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1. Introduction 
This present thesis is part of the research project “Antioxidative and 
Antigenotoxic Potential of Bile Pigments”, promoted by FWF, at the Department 
of Nutritional Sciences, University of Vienna.  
Gilbert‘s Syndrome (GS) is a condition with increased serum bilirubin levels 
(around >1 mg/dl) and is found in up to 17 % of the population. It is considered 
as harmless in adults. GS people have only a 30 % remaining activity of the 
enzyme hepatic uridine diphosphate glucuronosyltransferase (UGT1A1) and 
therefore, the circulating unconjugated bilirubin concentration is increasing.  
Recent studies already showed that bilirubin, the main bile pigment in organism, 
has an antioxidative potential in vitro and the ability to decrease oxidation of 
plasma. In a human study results showed a better protection of serum oxidation 
in GS compared to normal controls. Therefore, it is speculated that bilirubin 
works as antioxidant against oxidative stress and furthermore against DNA 
damage.  
The aim of this study was to observe whether people with Gilbert’s Syndrome 
have lower DNA damage than controls. The levels of oxidative DNA damage 
were measured by Comet assay in PBMCs.  
By now there is no literature available concerning GS and Comet assay. In this 
thesis first results on this background are shown.  
Research and lab work was made in collaboration with Nadja Antl and 
therefore, chapters “Literature survey” and “Material and Methods” were written 
together and are similar in both works.  
  
2 
  
2. Literature Survey 
2.1. Oxidative stress  
2.1.1. Free radicals 
Free radicals are molecules or fragments of molecules, which are characterized 
by a high reactivity and instability. The reactivity of free radicals is caused by 
unpaired electrons in the outer shell, which is not a desirable state for the 
molecule [VALKO et al., 2006]. In order to regain stability, free radicals deprive 
the missing electron randomly from other molecules.  
The most important class of free radicals in the biological system are radicals 
derived from oxygen, so called reactive oxygen species (ROS) and radicals 
derived from nitrogen, reactive nitrogen species (RNS) [DRÖGE, 2002]. 
Reactive oxygen species include radicals like the highly reactive hydroxyl 
radical (*OH), superoxide radical (O2
*-) and the non-radical hydrogen peroxide 
(H2O2), which is easily converted into a free radical [EVANS et al., 2004]. 
Reactive oxygen species in living organism play dual roles, deleterious at high 
concentrations and beneficial roles at low or moderate concentration. Beneficial 
physiological functions of reactive oxygen species are the defence against 
pathogens, second messenger in a number of signalling pathways and the 
induction of mitogenic response. Many responses mediated by ROS protect 
cells from oxidative stress. At high concentration ROS can cause damage to 
important cell structures including lipids and membranes, proteins and DNA 
(deoxyribonucleic acid) by attacking them comprising their natural function 
[VALKO et al., 2006]. 
The sources of ROS are either of endogenous or exogenous origin:  
Endogenous factors are by-products of normal cell metabolism. ROS can be 
released from the mitochondria during oxidative phosphorylation, from 
peroxisomes during degradation of fatty acids and from leukocytes during the 
defence mechanism against microbes and from the cytochrome p450 system, 
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which has mixed functions in the oxidation system. Also, mistakes during cell 
division can lead to the production of ROS [WU et al., 2004]. 
Exogenous sources for ROS production are life style factors like diet, alcohol, 
cigarette smoking, exercise and environmental factors like exposure to toxins 
and radiation [GIDRON et al., 2006].  
 
2.1.2. Free radicals and Oxidative stress 
As already mentioned free radicals are not deleterious at low or moderate 
concentrations. In healthy individuals, there is almost a balance maintained 
between oxidants and antioxidants [VALKO et al., 2006]. 
Antioxidants can inhibit oxidation of body cells and support the organism to 
protect DNA by donating e- for free radical detoxification. [MATÉS, 2000; SIES, 
1997] Antioxidants are of physiological relevance and can be either enzymatic 
or non enzymatic. Enzymatic antioxidant systems are for example superoxide 
dismutase (SOD), catalase (CAT) or glutathione peroxidise (GSH-Px). Non 
enzymatic antioxidants are vitamin E, vitamin C, carotinoids or serum proteins 
like uric acid and bilirubin. Some of these antioxidants are synthesised in the 
body, like glutathione, uric acid and bilirubin, some have to be provided 
alimentary, like vitamin C, E and β-carotin. [ELMADFA and LEITZMANN, 2004]  
An imbalance between oxidants and antioxidants occurs either by excessive 
production of ROS or deficient capacity of the antioxidants system, leading to 
an undesirable state, which is called “oxidative stress” (see Figure 1) 
[COLLINS, 2009]. 
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Figure 1: Oxidative Stress  (modified after ELMADFA and LEITZMANN, 2004) 
 
During oxidative stress in vivo ROS can attack important biomolecules. Cellular 
targets for oxidative modification include DNA, lipids and proteins. Which of the 
biomolecules will be modified depends on several factors such as location of 
ROS production, relative ability for the biomolecule to be oxidised and 
availability of metal ions. [EVANS et al., 2004]  
 
2.1.3. Oxidative stress and DNA damage 
The most important derivate of ROS, which causes damage to DNA is the 
hydroxyl radical (OH*-). OH*- is the most reactive form of ROS and able to react 
with all components of the DNA [VALKO 2006]. In the body the OH*- radical can 
be derived from H2O2, which can diffuse across membranes and through the 
cytosol. At normal state the strong oxidant H2O2 is converted into water and 
molecular oxygen by antioxidant enzymes, like the glutathione peroxidase, 
superoxide dismutase (SOD) or catalase (CAT). If transition metals such as 
copper [Cu] or iron [Fe] are present, H2O2 can be reduced to the highly reactive 
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*OH. A direct reaction with DNA is possible and harmful damage can occur. 
[ROBERTS and SINDHU, 2009] 
To date, more than 100 oxidised DNA products have been identified [VALKO et 
al., 2006]. Damaged products of DNA include single strand breaks (SSB), 
double strand breaks (DSB), base-less sugars or AP (apurinic/apyrimidinic) 
sites, DNA-Protein cross links and the modified DNA bases purine and 
pyrimidine. [EVANS et al., 2004]. DNA strand breaks cannot be specifically 
related to oxidation since they result from various forms of damage and might 
also present intermediates in the repair process. In contrary to DNA strand 
breaks oxidised bases are specific indicators of oxidative damage, reflecting the 
background damage caused by ROS in the cells [COLLINS, 2009].  
 
Figure 2: Double and single strand breaks in DNA [http://en.wikipedia.org/wiki/DNA_repair; access 
date: 20.5.2011] 
       
2.2. Methods for measuring DNA damage 
For detecting different endpoints of DNA damage a bunch of methods like the 
Comet Assay, the micronucleus Assay or 8-OxodG have been developed. 
Marker Method (abbreviation) 
8-OxodG HPLC-ECD, GC/MS, LC-MS/MS 
Sister chromatids Sister chromatid assay (SCEs) 
nucleoplasmatic bridges (NPBs) and 
nuclear buds (NBUDs) 
Micronucleus test (CBMN) 
Oxidised pyrimidines, 8-OxodG,  
Single and Double strand breaks 
Methods with enzymes like Single cell gel 
electrophoresis (SCGE) (Comet Assay) 
Table 1: Summary of methods for measuring DNA-damage [WAGNER and JAHREIS,2004; 
FENECH, 2007; WILCOSKY and RYNARD,1990] 
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2.2.1. Oxidised Purines (8-OxodG) 
Among the DNA bases purine and pyrimidine, guanine is most prone to 
oxidation. Throughout the oxidation of guanine, a hydroxyl radical is added to 
the heterocyclic structure of guanine at the 8th position (C8-OH-adduct radical) 
and releases an H-Atom forming the oxidation product 8-OxodG (8-Oxo-7,8-
dihydro-2’-deoxyguanosine). [WAGNER und JAHREIS, 2004] The existing keto-
enol tautomerism between the endproducts 8-OxodG and 8-OHdG (8-hydroxy-
2’-deoxyguanosine) favours the 8-OxodG product (see Figure 3) 
[VALAVANIDIS et al., 2009]. 
 
Figure 3: Forming 8-OxodG after reaction of 2´-desoxyguanosine with hydroxyl radicals 
[VALAVANIDIS et al., 2009] 
 
8-OxodG is one of the most important lesion of DNA caused by free radicals. 
Therefore, 8-OxodG is often used as a biomarker for oxidative stress and it is 
also considered as a risk factor for oxidative stress related diseases such as 
cancer, atherosclerosis and diabetes. [WU et al, 2004] 
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The lesion of 8-OxodG is particularly harmful, because it is able to structurally 
mimic thymine base and thus able to bypass replicative DNA polymerase which 
removes damaged bases before DNA replication. If 8-oxodG is not fully 
removed before replication, wrong base pairing occurs. Generally, adenine 
pairs with thymine and guanine pairs with cytosine, but due to oxidative 
modification of guanine, it pairs mistakenly with Adenine leading to guanine-
thymine-transversion (GT-transversion mutation). [DAVID et al., 2007] 
 
8-OxodG was first detected by Kasai and Nishimura in 1984 with high 
performance liquid chromatography (HPLC) and electron capture detector 
(ECD). Consecutively different methods for measuring 8-OxodG were 
developed. (See also Table 1) [WAGNER and JAHREIS, 2004] 
 
 HPLC-ECD (high pressure liquid chromatography-electron capture detector) 
A very sensitive (detection limit: 2 – 10 fmol) and correct method that has 
low costs of equipment and is commonly used. A disadvantage of this 
method is that it can only detect electrochemical active matters (like 8-
OxodG) [WAGNER and JAHREIS, 2004] and suffers from adventitious 
oxidation during sample preparation [COLLINS, 2009; ESCODD, 2003]. 
 
 GC/MS (gas chromatography/mass spectrometry) 
With gas chromatography and mass spectrometry most of the oxidised 
modifications are detectable (detection limit: 18 fmol). But to mention also 
some disadvantages it is a more expensive method and derivatisation is 
necessary. The obtained 8-OxodG levels are artificially increased what 
makes the interpretation of the results more complicated. [WAGNER and 
JAHREIS, 2004] 
Gas chromatography is therefore a not really suitable method to measure 
basal 8-OxodG in biological material [COLLINS, 2009]. 
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 LC-MS/MS (liquid chromatography-mass spectrometry/mass spectrometry) 
Liquid chromatography is theoretically the most powerful method with a 
detection limit of 7.5 – 10 fmol in contrast it is a very expensive method 
[WAGNER and JAHREIS, 2004]. But this method is also considered as 
relatively simple and sample pre-treatment is not absolutely necessary. LC-
MS/MS method is often preferred because of its specificity and high 
sensitivity [LEE et al., 2010]. It is a method that can measure more than one 
product from DNA oxidation and is therefore often used for quantitative 
analysis of the oxidized nucleosides [HENRIKSEN et al., 2009].  
 
2.2.2. Sister chromatid exchange (SCEs)   
Sister chromatid exchange (SCEs) is a process that occurs during DNA 
replication, where two sister chromatids, that are probably genotoxic harmed, 
break and rejoin with another one. SCEs occur naturally and spontaneous but 
can also be induced by genotoxic substances and therefore it is a method for 
measuring cell damage [WILSON and THOMPSON, 2007]. 
Sister chromatid exchanges can exchange apparently identical segments of 
DNA without known modification of cell viability or function. The SCEs has been 
widely used as an in vitro method for measuring the mutagenic potential of 
chemicals. In the last years interest was growing to use sister chromatid 
exchange also as marker of DNA lesions in humans that were exposed to 
certain types of chemical carcinogens. For the visualization of SCEs a different 
staining at the sister chromatids is important, as for example with the thymidine 
analog 5-bromodeoxyuridine (BrdU). See also Figure 4. [WILCOSKY and 
RYNARD, 1990] 
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Figure 4: Visualization of SCEs according to Wilcosky and Rynard (1990). [A] Chromosome in G0-
phase [B] First metaphase: After staining with BrdU each sister chromatid consists of one normal 
parent strand (dark lines) and one BrdU-substituted strand (dashed lines). [C] After mitosis: Two 
daughter cells. [D] Metaphase in second cell division: daughter cells are composed of one sister 
chromatid with a parent strand and one BrdU-substituted strand and the other one with both 
strands out of BrdU-Substitution. [E] Second mitosis. [WILCOSKY and RYNARD, 1990] 
 
2.2.3. Cytokinesis-block micronucleus cytome assay (CBMN) 
The cytokinesis-micronucleus (CBMN) assay is a method for measuring 
micronuclei (MNi), nucleoplasmic buds (NBuds) and nucleoplasmic bridges 
(NPBs) in cultured human cells.  
The micronucleus test in vivo was developed by Schmid and co-workers and is 
a method for screening chemical exposure and their chromosome-breaking 
effects [SCHMID, 1975]. The assay has been improved by M. Fenech and 
colleagues for use in lymphocytes and so today micronucleus test can be used 
for measuring DNA damage, cytostasis and cytotoxicity [FENECH, 2007]. 
The micronucleus assay can be used with bone marrow, peripheral blood 
erythrocytes, peripheral blood lymphocytes and buccal cells and is now one of 
the best established in vivo cytogenetic assays [FENECH, 2000].  
Micronuclei are formations of small membrane bound DNA fragments or whole 
chromosomes that are unable to travel to the spindle poles during mitosis. 
Since this method has a good reliability and reproducibility it is a standard 
mutagenic test system for the detection of genetic toxicology [FENECH, 2000; 
FENECH, 2007]. 
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Nucleoplasmic bridges and nucleoplasmic buds (see Figure 5) provide an 
additional and complementary measure of chromosome rearrangement that can 
be scored together with the micronucleus count [FENECH, 2000]. 
With the CBMN assay it is possible to obtain the frequency of chromosome 
breaks and chromosome loss with MNi as biomarker. Measurements of 
chromosome rearrangements like dicentric chromosomes (nucleoplasmatic 
bridges (NPBs) as biomarker for DNA misrepair) or gene amplifications (nuclear 
buds (NBUDs) as biomarker) as well as necrosis and apoptosis are possible 
[FENECH, 2007]. 
Bonassi and co-workers for example found that an increased frequency of 
micronuclei in peripheral blood lymphocytes can probably predict cancer risk in 
humans, especially urogenital and gastro-intestinal cancer [BONASSI et al., 
2007]. 
The principle of this assay is that cells are stimulated for division by PHA and 
after an addition of cytochalasin B, a mycotoxin for blocking cytokinesis the cell 
growth is stopped at a binucleated state. If there are chromosomal damage 
micronuclei, NPBs, NBUDs are formed. The cell suspension is paced on slides 
and after staining the cells are analysed with a microscope in order to count the 
existing DNA damage products. [FENECH, 2000] 
 
 
Figure 5: Visualization of micronuclei assay: [a] Micronuclei in anaphase (whole chromosomes 
and chromosome fragments); [b] Formation of nucleoplasmic bridges (NPBs); [FENECH, 2000] 
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2.2.4. Single cell gel electrophoresis (SCGE) (Comet Assay) 
The Comet Assay, also called single cell gel electrophoresis (SCGE), was first 
carried out under neutral conditions by Östling and Johanson in 1984. The 
SCGE under neutral conditions was only for analysing double strand breaks. 
Therefore, a few years later in 1988 Singh et al. described a similar method but 
using alkaline conditions and a sensitive method for measuring both, single- 
and double-strand breaks in DNA, was found. [DHAWAN et al., 2009] 
The Comet Assay is named after the receiving image, which occurs after 
staining and looks like a “Comet”. The head of a Comet contains intact DNA tail 
that is build by damaged or broken pieces of DNA. [PIPERAKIS, 2009] 
 
The advantages of the Comet Assay include  
 the high sensitivity for detecting low levels of DNA damage,  
 the small sample size (from 10000 to 50000 cells),  
 the flexibility to use proliferating as well as non-proliferating cells, 
 low costs, 
 the easy and fast application, 
 that results can be obtained on the same day,  
 that fresh and frozen samples are suitable and 
 virtually any eukaryotic cell population can be analysed. [DHAWAN et 
al., 2009; PIPERAKIS, 2009] 
 
Some limitations and disadvantages of the Comet Assay might be  
 that also non-oxidised DNA-damage is detectable, 
 reproducibility is low, [WAGNER and JAHREIS, 2004] 
 aneugenic effects (that are maybe a possible mechanism for 
carcinogenicity) and epigenetic mechanisms of DNA damage are not 
detected, 
 single cell data (which may be rate limiting), 
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 small cell sample (leading to sample bias) and 
 technical variability. [DHAWAN et al., 2009] 
 
Although the Comet Assay may be less precise than for example HPLC the 
advantages of the Comet Assay predominate the disadvantages and the SCGE 
has been widely used in the last years in many different fields of research. By 
using this assay it was possible to analyse the impact of oxidative stress in 
human diseases, to detect effects of environmental exposure to genotoxins and 
also to clarify the importance of antioxidants in our nutrition. [COLLINS, 2009] 
 
Procedure of the Comet assay: 
The key principle of the method is the migration of the damaged DNA in an 
electric field at alkalised pit and measures the different intensities of the formed 
“comets” (see Figure 6). 
For the procedure in the single cell gel electrophoresis cells (for example 
isolated peripheral human lymphocytes) are placed on a microscope slide with 
agarose. They have to be lysed with detergent of high salt to form nucleoids, 
which contain non-nucleosomal but still supercoiled DNA. Cells are exposed to 
an electric field in the electrophoresis and fragments of DNA can then migrate 
toward the anode and forming a “comet tail”. The amount of DNA in the tail 
represents the frequency of strand breaks and the comet assay is therefore a 
method for measuring DNA damage. [COLLINS et al., 1997] 
DNA strand breaks are then visualized with fluorescence microscopy after 
staining with a DNA-binding dye, such as ethidium bromide. Ethidium bromide 
is more efficient for double strand breaks than for single strand breaks. 
[COLLINS, 2004] 
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Figure 6: Photomicrographs of DNA from human lymphocytes after electrophoresis (left: no 
“comet”: no DNA migration; right: “comet”: damaged DNA, after treatment with ENDOIII)  
 
By using specific enzymes it is possible to make the assay more specific and 
sensitive since these enzymes can recognize a particular kind of damage. 
Endonuclease III (ENDOIII) can be used to detect oxidized pyrimidines and 
formaminopyrimidine DNA glycosylase (FPG) to detect the major purine 
oxidation product 8-oxoguanine (8-OxoG) as well as other altered purines 
[Collins, 2004]. 
After treatment with H2O2 mainly DNA strand breaks are occurring but also 
some oxidation in bases can be detected [COLLINS, 2009]. The receiving 
amount of DNA breaks is then characteristic for the changes in the sensitivity of 
the cells towards exogenous oxidative DNA damage [HOELZL et al., 2009].  
 
2.3. Bile pigments 
2.3.1. Bilirubin structure 
The fundamental structure of bilirubin composes four covalent connected 
pyrrole rings, forming an open, linear, tetrapyrrolic chain. The two outer pyrrole 
rings carry a polar lactam (-CO-NH) group and the central pyrrole rings carry a 
polar propione sidechain (-COOH) (see Figure 7). [VITEK & OSTROW 2009] 
Bilirubin and biliverdin are flexible molecules, which can assume different 
molecular conformations. Bilirubin preferable has a folded ridge tile 
conformation, which is caused by the formation of intermolecular hydrogen 
bonding between carboxyl group and other polar groups in the molecule. This 
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constellation is responsible for the lipophilic character of bilirubin at 
physiological pH, as the polar groups are in a way ‘neutralized’. [MC DONAGH 
2010a] 
 
Figure 7: Two- and three-dimensional structures of (1) bilirubin and (2) biliverdin [BULMER et al., 
2008b] 
 
2.3.2. Heme Metabolism 
Bilirubin, a colourful endogenous compound, is entirely derived from the 
breakdown of heme in the body.  
Heme is well known as a component of hemoglobin in red blood cells. 
Furthermore a wide range of enzymes like cytochrome P450, catalase and 
peroxidase contain heme as a prosthetic group, which is released during their 
turnover. [SEDLAK & SNYDER 2004] 
Red blood cells have a limited life span and are decomposed in the 
reticuloendothelial system after 120 days whereby heme is released. Each day 
approximately 300 mg (0.7 mg/kg) of unconjugated bilirubin (UCB) are 
produced which equates the amount of destructed heme in the body. 75 % of 
de novo UCB is derived by the destruction of senescent red blood cells and the 
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remaining 25 % are derived from non-hemoglobin heme proteins [VITEK 
&OSTROW 2009]. UCB is efficiently metabolised in the intestine by the action 
of anaerobic bacteria. The products of bacterial metabolism so called 
urobilinoids like stercobilin are mainly eliminated in the stool – excretion of 
yellow-orange coloured stercobilin 40-280 mg/d. Small proportions of 
urobilinoids undergo enterohepatic circulation where a small part reaches the 
kidney and is excreted in the urine in the form of urobilin or urobilinogen 
approximately 0.64 mg/24h urine. In the case of high heme decomposition or 
liver damage the excretion of urobilin or urobilinogen in the urine is increased 
[PETRIDES, 2007]. 
 
The breakdown of heme is a multistep process and involves the two major 
enzymes, microsomal heme oxygenase (HO) and cystolic biliverdin reductase 
(BVR) (see Figure 8) [VITEK & OSTROW 2009]. 
 
Figure 8: Metabolism of heme [BULMER et al., 2008b] 
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The first step of heme cleavage which is also the rate limiting step is mediated 
by HO. Heme oxygenase oxidatively cleaves the heme ring at the methin bridge 
between pyrrolring A and B forming the direct precursor of bilirubin, green 
coloured biliverdin (BV), carbonmonoxid (CO) and Iron (Fe2+). Fe2+ can be 
reused and biliverdin is quickly reduced by biliverdin-reductase to unconjugated 
bilirubin (UCB). [VITEK & OSTROW, 2009] 
With the glucuronyl-transferase (UGT1A1) bilirubin can be conjugated to 
bilirubin diglucuronide. If this enzyme is not working properly it can lead to an 
increase in bilirubin levels and bilirubin associated diseases like Gilbert’s 
syndrome, crigler-najjar syndrome or neonatal hyperbilirubinaemia. (See also 
chapter 2.4.). [PETRIDES, 2007] 
Biliverdin is only a transient intermediate. It is entirely and quickly reduced by 
biliverdin reductase, which occurs as a complex with membrane bound HO and 
in the cytosol facilitating the quick reduction of biliverdin. [MC DONAGH, 2010a] 
Colourfully the metabolism of bilirubin is displayed during bruising, where blue-
red stained heme is followed by blue-green colour of biliverdin and by yellow 
colouration of bilirubin. Conjugated systems of double-bondings cause the 
colouration of these porphyrin molecules. [KOOLMAN and RÖHM, 2002; 
BULMER et al., 2008b] 
Unconjugated bilirubin that is referred to as “indirect bilirubin” is poorly soluble 
in water. UCB needs to be tightly bound to serum albumin in order to be 
transported to the liver via the systemic circulation. Before entering the liver, 
bilirubin is dissociated from its carrier protein albumin and taken up by the 
hepatocyte across the sinusoidal membrane. In the cytosol of hepatocytes 
bilirubin binds to ligandin with high affinity and is transported to the 
endoplasmatic reticulum (ER). In the ER unconjugated bilirubin is converted into 
its water soluble form “direct bilirubin” by conjugation. Bilirubin is conjugated 
with glucuronic acid on sugar molecules by UDP glucuronosyl transferase 
(UGT1A1) forming bilirubin monoglucuronide and diglucuronides [KAMISAKO, 
2000; MC DONAGH, 2010a]. 
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The water soluble glucuronide derivates are excreted into the bile by the 
canicular ATP-dependent transport protein MRP2 (multidrug resistance 
associated protein 2) [MC DONAGH, 2010a].  
In the intestine, bilirubin mono and di-glucuronide are hydrolysed by the action 
of anaerobic bacteria (β-Glucuronidasen). Bilirubin is reduced stepwise to 
stercobilinogen, which is a colourless compound that is partly oxidised to 
yellow-orange coloured stercobilin. Most of the end products of bilirubin 
metabolism are excreted with the stool, a small part is reabsorbed and 
undergoes enterohepatic circulation [PETRIDES, 2007; KOOLMAN and RÖHM, 
2002]. 
 
2.3.3. Physiological concentrations of bilirubin 
The physiological concentration of bilirubin in plasma is about 0.1 – 1.2 mg/dl 
(1.7 – 20.5 µmol/l) [PETRIDES, 2007]. Serum bilirubin levels vary significantly 
with gender, men in general show significantly higher serum bilirubin levels 
(0.72 mg/dl) compared to women (0.52 mg/dl) [ZUCKER et al., 2004]. 
“Unconjugated Bilirubin”, which is tightly bound to serum album, demonstrates 
the principle bile pigment in mammals and accounts 90 % of total circulating 
bilirubin in the body and less than 0.01 % of total bilirubin is unbound (free 
bilirubin, Bf). [VITEK and OSTROW, 2009] 
 
2.4. Hyperbilirubinaemia 
As already discussed bilirubin that is generated during the decomposition of 
erythrocytes is called unconjugated bilirubin. It is immediately bound to albumin 
in blood and transported to liver. In the liver unconjugated bilirubin is conjugated 
to glucuronic acid, consequently gets water soluble and is finally called 
conjugated bilirubin. A mutation in the gene promotor region of bilirubin-uridine-
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diphosphate-glucuronyl transferase (UGT1A1) can cause hyperbilirubinaemia.  
[THOMPSON, 2003] 
Hyperbilirubinaemia is a benign or malign condition that is caused by elevated 
bilirubin levels.  
Mild rises in bilirubin levels can be caused by:  
• Gilbert’s syndrome:  >17.1 µmol/l unconjugated bilirubin [BULMER et al., 
2008a] 
• Rotor syndrome: increased (51.3 - 171 mg/dl) levels of conjugated bilirubin 
[MAIER, 2000]     
Strong rises in bilirubin can be caused by: 
• Neonatal hyperbilirubinaemia (jaundice): conjugated and unconjugated 
bilirubin levels can be increased [THOMPSON, 2003] 
• Crigler-Najjar-Syndrome: >335 µmol/l unconjugated bilirubin [BULMER et 
al., 2008a] 
• Dubin-Johnson Syndrome: 51 – 257 µmol/l conjugated bilirubin [GARTUNG 
and MATERN, 1999] 
Bilirubin levels can also rise by haemolysis (increased breakdown of 
erythrocytes), hepatitis, choledocholithiasis, cirrhosis and chemotherapy 
[GARTUNG and MATERN, 1999]. 
 
2.4.1. Gilbert’s syndrome 
Gilbert’s syndrome (GS) is also called “Morbus-Meulengracht” or “Icterus 
intermittens juvenilis”. Men are four times more often affected than women 
[GARTUNG and MATERN, 1999]. It is the most common hereditary cause of 
increased bilirubin and is found in up to 3 – 17 % of the population [BULMER et 
al., 2008a]. 
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Generally Gilbert’s syndrome is considered as harmless in adults, although an 
incidental finding of hyperbilirubinemia may raise the possibility of liver disease 
[BOSMA et al, 1995]. 
The condition is characterized by a hereditary mutation in the gene promoter for 
hepatic uridine diphosphate glucuronosyltransferase (UGT1A1) [BULMER et al., 
2008a]. As mentioned before UGT1A1 is responsible for glucuronidation of 
UCB. In persons with GS a 30 % remaining activity of the enzyme is found. 
Therefore, the circulating unconjugated bilirubin concentration is increasing. 
[BOSMA et al., 1995] 
Bilirubin has an antioxidative potential in vitro [NEUZIL and STOCKER, 1994] 
and the ability to decrease oxidation of the plasma [FREI et al., 1988]. Results 
of a human study showed a better protection of serum oxidation in GS as for 
controls. [BULMER et al., 2008a]  
Elevated levels of serum bilirubin may play an important role in the prevention 
of ischemic heart disease. Due to the antioxidant capacity of bilirubin a possible 
protection of lipids and lipoproteins against oxidation is assumed. Therefore, 
elevated bilirubin levels, like in GS, might protect against atherosclerosis. 
[YESILOVA et al., 2008] 
Another study by Vitek at al. showed that high serum bilirubin levels are related 
to low urinary excretion of biopyrrins, an oxidative metabolite of bilirubin [VITEK 
et al., 2007]. Urinary excretion of biopyrrins is correlated with oxidative stress 
[SHIMOHARADA et al., 1998] and therefore, correlation with cardiovascular 
diseases (CVD), like heart failure [HOKAMAKI et al., 2004] or coronary spastic 
angina [MORITA et al., 2001]. These studies proved that people with GS are 
probably better protected against oxidative stress and CVD because of low 
urinary excretion of biopyrrins.  
Schwertner et al. also described that high serum total bilirubin levels decrease 
the risk of coronary artery diseases [SCHWERTNER et al., 1994]. The first 
study on cardiovascular heart disease (CHD) risk and especially Gilbert 
syndrome patients was carried out by Vitek et al. in 2002. In this study results 
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showed that only 2 % of people with GS were found to have CHD compared to 
12.1 % of the general population. First results concerning the decreased risk of 
CHD particularly in GS patients were shown. [VITEK et al., 2002]   
 
2.4.2. Neonatal hyperbilirubinaemia 
Neonatal hyperbilirubinaemia is leading to jaundice, which means the yellowing 
of the skin and other tissues of a newborn infant. Cause of neonatal jaundice is 
an imbalance between UCB production and elimination [AHLFONS et al., 2009]. 
High serum bilirubin concentrations can be found around 2 – 5 days after birth 
and the bilirubin levels normally don’t exceed a level of 90 µmol/l. In about 70 % 
of newborns this condition exists but bilirubin levels decline to a normal value 
after some days and therefore neonatal hyperbilirubinaemia is mostly harmless 
[THOMPSON, 2003]. 
Normally jaundice in adults is harmless but as the tissues protecting the brain 
are immature in newborns, neonatal jaundice can cause acute bilirubin 
encephalopathy (ABE) and this can lead to kernicterus or death. Consequences 
of kernicertus can be for example athetoid cerebral palsy, auditory dysfunction, 
ocular movement disorders or dental enamel dyslasia. Phototherapy is a well 
established method for enhancing UCB elimination in order to prevent ABE and 
kernicterus.  [AHLFONS et al., 2009] 
 
2.4.3. Crigler-Najjar-Syndrome (CNS) 
There are two syndromes of more severe unconjugated hyperbilirubinaemia, 
namely the rare type 1, which often leads to neonatal death, and the more 
common and more harmless type 2. Both are caused by severe deficiency of 
the enzyme UGT1A1 [THOMPSON, 2003]. 
In type 1 the disease is autosomal recessive inherited with an incidence of 
1:10000 [GARTUNG and MATERN, 1999] and in neonates this can rapidly 
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cause jaundice in the first days with an unconjugated bilirubin level from 350 to 
950 µmol/l. A correct treatment is necessary to avoid development of 
kernicterus or brain damage.  
Crigler-Najjar-Syndrome type 1 desires a whole body blue-light phototherapy for 
16 h daily. Another rehabilitation would be plasmapheresis until a liver 
transplantation is possible, as a definitive cure. [THOMPSON, 2003] Another 
standard treatment for Crigler Najjar Syndrome would be the Phenobarbital 
therapy. As in many of these patients a defect of the production of the enzyme 
UGT1A1 occur, an addition of Phenobarbital can stimulate enzyme production 
and therefore, helps to remove bilirubin. But for some people with CNS reduced 
enzyme production is not the only cause and for these patients Phenobarbital 
therapy wouldn’t provide any benefits. 
[http://carmonet.50webs.com/CNS/phenobarb.html; access date: 16.06.2011] 
Crigler-Najjar-Syndrome type 2 can either be inherited dominant with 
incomplete penetrance or autosomal recessive. On the contrast to type 1 
bilirubin levels are lower (<350 µmol/l) [THOMPSON, 2003] and the rest activity 
of the UGT1A1 can be <10 % compared to normal [GARTUNG and MATERN, 
1999]. Brain damage doesn’t occur and persistent mild jaundice is only noticed 
in childhood.  [THOMPSON, 2003]    
Drugs like penicillin or salicylates have to be avoided in people with Crigler-
Najjar-Syndrome, because they have the ability to displace unconjugated 
bilirubin from albumin [THOMPSON, 2003]. 
 
2.4.4. Dubin-Johnson Syndrome and Rotor Syndrome 
Dubin-Johnson and Rotor Syndrome are rare forms of non-haemolytic and 
autosomal recessive disorder with conjugated hyperbilirubinaemia without 
cholestasis [THOMPSON, 2003]. 
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In the Dubin-Johnson Syndrome bilirubin levels are between 51 – 257 µmol/l 
and usually it is asymptomatic but may be diagnosed by incidental finding in 
early infancy. Generally this syndrome is harmless but jaundice can occur 
sometimes during pregnancy or intake of hormonal contraceptives. [GARTUNG 
and MATERN, 1999] 
A typical indication of Dubin-Johnsons Syndrome is an accumulation of black 
pigments in the liver hence, at laparoscopy the liver appears strikingly black. 
Another diagnostic finding is that the urinary coproporphyrin excretion is either 
increased or decreased. [THOMPSON, 2003] 
The Rotor-Syndrome is a disorder similar to the Dubin-Johnson Syndrome with 
unknown origin and unpigmented liver cells. The main symptom is a non-itching 
jaundice and elevated conjugated bilirubin serum levels. [THOMPSON, 2003] 
 
2.5. Protective role of bile pigments in literature 
2.5.1. First findings and bilirubin as antioxidant 
As already mentioned elevated bilirubin levels that exceed the liver capacity for 
the excretion can cause toxicity and acute or neurological dysfunction. In fact 
these patients rarely suffer from bilirubin toxicity and scientists have found that 
bilirubin acts dose dependent and therefore, might also have a protective role. 
[BULMER et al., 2008b] 
In the last two decades the beneficial role of bile pigments gained high interest 
and much research was done in order to confirm their physiological importance.  
The antioxidative effects of bilirubin were already demonstrated in the 1950s, 
where it was shown that small quantities of bilirubin or biliverdin can stabilize 
vitamin A or β-carotene and effectively protect lipids, especially linoleic acid 
from oxidation [BERNHARD et al., 1954].  
In the same experiments it was shown that unconjugated bilirubin reacts 
efficiently with peroxyl radicals in homogenous solutions. Furthermore a 
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correlation with membrane-bound α-tocopherol was found concluding that 
bilirubin and biliverdin may act in synergism with α-tocopherol. In the absence of 
α-tocopherol lipid peroxidation was increased and with just small amounts of 
bilirubin or biliverdin this oxidation was inhibited. Stocker and colleagues 
illustrated that the antioxidant capacity of bilirubin exceeds the one of Vitamin E 
that is meant to be the strongest antioxidant toward lipid peroxidation so far. 
[STOCKER and PETERHANS, 1989] 
The synergistic effect was also proven in a further study. Bilirubin inhibited the 
formation of cholesterylester hydroperoxide (CE-OOH), the oxidation product of 
LDL, by scavenging the alpha tocopherol radical (TO) in LDL.  [NEUZIL and 
STOCKER, 1994]  
Additionally other findings showed the idea of bilirubin reacting with ROS. A 
reason why bilirubin can react with reactive oxygen species is that it contains a 
pair of reactive hydrogen atoms and acts therefore as H-donator. [STOCKER, 
2004] 
Recent studies demonstrated that bilirubin also has anti-mutagenic, anti- viral, 
anti-inflammatory and anti-proliferative properties. [BULMER, 2008; ZUCKER et 
al., 2004]  
It is assumed that the antioxidant effect of bilirubin originates from the redox-
recycling with biliverdin. As already mentioned bilirubin is oxidised to biliverdin 
and then recycled by biliverdin reductase to bilirubin [BARANANO et al., 2002; 
McDonagh, 2010b]. In the study of Baranano and co-workers especially the 
formation of biliverdin during 2,2’-azobis (2-amidinopropane) hydrochloride 
(AAPH) oxidation of bilirubin is ment to be the basic principle of this theory. 
[BARANANO et al., 2002] 
This biliverdin-bilirubin recycling mechanism explaining for the antioxidative 
protection is becoming more accepted. [VITEK and OSTROW, 2009] 
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2.5.2. Albumin-bound bilirubin 
A strong evidence exists that albumin bound bilirubin protects proteins against 
oxidative damage by several types of reactive oxygen and nitrogen species 
(RONS). Already in 1987 an in vitro study by Stocker et al. demonstrated that 
free fatty acids, especially linoleic acid, transported by albumin can be protected 
from oxidative damage. The albumin-bound bilirubin increases with specificity 
and reactivity against RONS and this result in an elevated protection of plasma 
proteins and lipids. In this in vitro study the antioxidative effect of bilirubin in 
plasma was also compared with uric acid and vitamin C. The results indicate 
that bilirubin has the same antioxidative effect as uric acid but has a weaker 
effect compared to vitamin C. But this was an in vitro study and still more 
investigations would be needed to demonstrate this theory. [STOCKER et al., 
1987] 
To sum up, there is of course already some evidence that prove the antioxidant 
capacity of bile pigments in vitro but in fact it is necessary to observe whether 
this action remains also in vivo situations.  
There are only a few in vivo studies illustrating the protective role of bile 
pigments. One of these was published by Dennery and co-workers (1995). In 
this study hyperbilirubinaemic Gunn rats were exposed to a hyperoxia 
(>95 % O2) atmosphere for 3 days.  Oxidative markers were inversely 
correlated to serum bilirubin concentrations. [DENNERY et al., 1995]  
Another important work demonstrating antioxidative role of bilirubin in vivo was 
published by Noriega et al [2003]. They examined the effects of bilirubin 
(5 mmol/kg body weight) in aminolevulinic acid (ALA) induced liver damage in 
Wistar rats by intraperitoneal injection. This study showed that bilirubin can act 
as an efficient antioxidant against oxidative cell damage induced by ALA. 
[NORIEGA et al., 2003]  
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2.5.3. Bilirubin as protector for cardiovascular diseases 
Bulmer et al. (2007) investigated bilirubin as protector for cardiovascular 
diseases in patients with GS. The study was demonstrating that people with GS 
have improved resistance to serum oxidation and thus a reduced prevalence of 
cardiovascular disease compared to a control group. In conclusion it was 
suggested that higher levels of bilirubin can increase circulating antioxidant 
status and improve resistance to serum oxidation and may protect from 
prevalence of developing cardio vascular diseases (CVD). [BULMER et al., 
2008a] 
Some other studies showed that there is a low prevalence of coronary artery 
disease or ischemic heart disease in people with GS or just in general higher 
bilirubin levels. There is probably an increasing serum antioxidant capacity in 
people with higher serum bilirubin levels that prevent the occurrence of 
ischemic heart diseases. [VITEK et al., 2002; SCHWERTNER et al., 1994] A 
negative correlation between serum bilirubin levels and atherosclerosis was 
shown and these results might indicate the importance of bilirubin in the 
prevention of cardiovascular diseases or in general oxidative-stress mediated 
diseases. [NOVOTNY and VITEK, 2003] 
 
2.5.4. Bilirubin and DNA damage and cancer 
Overwhelming amounts of reactive oxygen species of endogenous or 
exogenous origin can cause damage to DNA. DNA lesion that remains 
unrepaired, increase the prevalence of mutations which play a key role during 
carcinogenesis.  
Bilirubin was shown to be a strong antioxidant that can prevent the oxidation of 
several biomolecules. There are only few studies which show the protective 
effect of bilirubin towards DNA oxidation and its role in the possible prevention 
in the etiology of cancer. The few numbers of studies, which investigate the 
effect of bilirubin levels, deliver conflicting results [ZUCKER et al., 2004]. 
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In the study of Asad et al. (2000) it was shown, that 50 µM of bilirubin was able 
to reduce the amount of oxidative DNA single strand breaks in calf thymus DNA 
induced by L-Dopa-Cu(II) by 50 %. A concentration of 20 µM bilirubin reduced 
the generation of hydroxyl radicals by 30 %. The results of this study suggest 
that any increase from normal bilirubin levels under conditions of oxidative 
stress would be able to afford protection of cellular DNA from L-Dopa-Cu-(II)-
mediated damage. [ASAD et al., 2000] 
Two years later (2002) the same research group of Asad and co-workers 
showed, that bilirubin has pro-oxidant effects upon DNA due to its ability to bind 
with  the transition metal ions Cu(II) and in the following form a bilirubin CU(II)-
DNA complex which causes oxidative DNA cleavage. [ASAD et al., 2002] 
Throughout a study by Rao et al. additionally the effect of bilirubin on DNA 
damage was investigated using the comet assay. Cells treated with bilirubin 
showed a typical comet tail indicating that bilirubin causes DNA damage. This 
study showed that bilirubin has anti-cancer activity as a prooxidant. [RAO et al., 
2006] 
In a Belgian prospective study the correlation of serum bilirubin and 10-year 
mortality risk including all cause, cardiovascular and cancer mortality was 
assessed in a Belgian population. The results showed that men with higher 
serum bilirubin levels had a significant reduced risk of non-lung cancer 
mortality. In women the same trend was observed but lacking statistical 
significance. There was no significant association detectable between serum 
bilirubin and cardiovascular mortality in neither men nor women. [TEMME et al., 
2001] 
In the USA, a prospective study on the potential chemopreventive function of 
bilirubin was investigated by Zucker et al. (2004). Data of the study showed that 
bilirubin levels vary significantly with gender, race and smoking status. Men 
have higher bilirubin levels compared to women. Serum bilirubin levels were 
lower in active smokers compared to non-smokers. Total serum bilirubin levels 
were also lower in subjects which reported prior nondermatological cancer in 
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comparison to subjects who did not have a history of nondermatological 
malignancy. The results of the study showed, that an increase in serum bilirubin 
by 1.0 mg/dl leads to a decreased prevalence of colorectal cancer (odds 
ratio: 0.257). The inverse relationship between serum bilirubin and colorectal 
cancer was more robust for women. There was also an inverse relationship 
between serum bilirubin and non-gastrointestinal cancers but at a lower level 
(odds ratio: 0.809). [ZUCKER et al., 2004] 
Very recent a cohort study examined the relationship between serum bilirubin 
levels and respiratory diseases and lung cancer among adults in UK. Incidence 
of lung cancer was assessed and the results showed that an increase in 
bilirubin level of 0.1 mg/dl was accompanied by an 8 % decreased lung cancer 
incidence in men and 11 % decreased lung cancer incidence in women. 
[HORSFALL et al., 2011]  
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3. Material and Methods 
3.1. Study design and in- and exclusion criteria 
In the present case-control-study 45 subjects with Gilbert’s syndrome (GS) and 
39 healthy persons as control group (C) were included. 16 persons could not be 
allocated to one of the groups clearly due to their UCB level very close to 
1 mg/dl. There was a difference between first and second blood sampling in 
reaching threshold values. For a clear allocating an additional blood sampling or 
determination of genotype would be needed. The aim of the study was to 
observe whether people with GS have a lower DNA damage than controls. 
Cases and controls were matched for age and sex. The experimental design is 
summarized in Figure 9. 
 
 
Figure 9: Illustration of the experimental design 
* The group “Not definable” is explained particularly in chapter 3.4. 
 
Participants were recruited by information-sheets in different buildings and 
places (hospitals, universities, pharmacies ...). In order to assess relevant 
parameters, blood was withdrawn from all participants at the beginning of the 
study at the General hospital (AKH). Together with questionnaires the inclusion 
and exclusion criteria were checked. 
Total 
Participants
(n=100)
Case                                       
Participants with  
Gilbert's Sydrome
(n=45)
Elevated blood 
level of UCB
Control 
(n=39)
Normal blood level 
of UCB
Not definable*
(n=16)
level around 
splitting value of 
UCB
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A second blood sampling was done at the AKH for the main project and besides 
urine collection, buccals cells were obtained. 
The blood samples were transported immediately to the Department of 
Nutritional Sciences at the “University of Vienna” in order to carry out the Comet 
assay, one of the favoured methods for measuring DNA damage in peripheral 
blood mononucleated cells (PBMCs). With the Comet assay it was observed 
whether people with GS are better protected against oxidative DNA damage 
than controls with normal bilirubin levels.  
Before the comet assay was carried out cells had to be isolated from whole 
blood and counted. See chapter 3.1.1 and chapter 3.1.2. 
 
Inclusion criteria: 
• Age: 20-80 years 
• total bilirubin level > 1.2 mg/dl [20.52 µmol/l] (GS) 
• unconjugated bilirubin level  > 1.0 mg/dl [17.1 µmol/l] (GS) 
• total bilirubin level <1.2 mg/dl [20.52 µmol/l] (Control) 
• unconjugated bilirubin level <1.0 mg/dl [17.1 µmol/l] (Control) 
• Gamma-Glutamytransferase (GGT) <39 U/l (women) <66 U/l (men) 
• Alanin Aminotransferase (ALT) <35 U/l (women) <50 (men) 
• Aspartat Aminotransferase (AST) <35 U/l (women) <50 U/l (men) 
• Moderate fitness 
 
Exclusion criteria: 
• < 20 years or > 80 years 
• Cardiovascular diseases 
• Hepatitis B/C 
• Liver diseases 
• Cholelithiasis 
• Haemolysis 
• Heart diseases 
• Chronically kidney illness 
• Acute tumor 
• Diabetes Mellitus 
• Supplementation of antioxidant within the last 4. Weeks before the first 
blood sampling 
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• No intake of drugs which affect liver parameters (eg. Probenecid, 
Rifampicin) within the last 5 weeks before the first blood withdrawal 
• Smokers >5 Cigarettes a day 
• People with organ transplantation 
• Competitive athletes (>10 hours training per week) 
 
3.1.1. Isolation of peripheral blood mononucleated cells 
• Whole Blood was sampled by venipuncture in heparinized tubes. 
• 7 ml of anticoagulant whole blood was pipetted in 12 ml Leucosep tubes. 
• Tubes were centrifuged at 1000 rcf for 15 Min. at 16 °C. (without brake) 
• The enriched fraction of lymphocytes, in particular peripheral blood 
mononucleated cells (PBMCs) were gently pipetted into a 15 ml 
centrifuge tube and filled up with 4 °C cold PBS-Buffer to a total volume 
of 15 ml. From here all steps were done on ice. 
• Tubes were centrifuged at 304 rcf for 15 Min. at 22 °C. (with brake) 
• Supernatant was discarded and PBMC pellet was washed in 10 ml of 
PBS-buffer. 
• Tubes were centrifuged at 304 rcf for 10 Min. at 22 °C. (with brake) 
• Supernatant was gently discarded and PBMC pellet was suspended in 
1 ml of PBS for cell counting.  
 
3.1.2. Cell counting determination 
To ensure a sufficient cell number per slide and to prevent overlapping of cells 
(if cell concentration is too high) a defined cell concentration of 1x 106 cells/ml is 
necessary for the comet assay procedure and a total suspension volume of 
250 µl. For cell count determination we used the automated cell counter 
“Countess” from Invitrogen. 
A cell suspension of appropriate concentration was needed to be prepared 
(approx. 106 cells/ml) and therefore 20 µl of cell suspension was diluted in 60 µl 
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PBS-buffer in a cup. 10 µl cell suspension was mixed with 10 µl 0.4 %Trypan 
blue (1:1). Finally, 10 µl were transferred in a chamber on a slide and inserted 
into the “Countess Invitrogen”. 
 
3.2. General principles of the Comet assay 
Comet assay is a widely used method for measuring DNA damage. The cells 
are embedded in agarose on a microscope slide. Lysis is used for removing 
membranes, cytoplasm and nucleoplasm. After treatment with H2O2 DNA strand 
breaks are occurring and different enzymes are used to detect oxidised 
pyrimidenes (ENDOIII) and oxidised purines (FPG).  
In an electric field at an alkalised level (electrophoresis), damaged DNA 
migrates faster than the compact and undamaged DNA. After staining, the 
different intensities of the formed “comets” can be evaluated with a fluorescence 
microscope. [COLLINS, 2004] 
 
3.3. Comet Assay 
3.3.1. Equipment for Comet Assay 
Material Company Product number 
Analytical balance Mettler AT201 
Balance  Mechatronics Austria 
GmbH 
41107690 
Calibration solution (pH buffer 
solution ±0.01pH) 
HANNA instruments  
Centrifuge Eppendorf 5417R 
Computer   
Countess-automated cell counter  Invitrogen  
Countess-cell counting chamber 
slides 
Invitrogen  
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Drying chamber Memmert GmbH Modell 500; D06061 
Electrophoresis Biozym Serial no: C5 
08091040; Stock 
Code: CSL-10M40 
Examination gloves Microflex  
Heating Plate/Magnetic stirrer  Heidolph MR 3001K 
Microscope Zeiss Germany, Hitachi  
Microscope slides VWR-Supplier 
Partnership for 
Customer Solutions 
ECN 631-1551 
Microscope Cover glasses 
(22x22 mm, 20x20 mm) 
VWR ECN 631-1570 
Microwave  Elta GmbH Germany MW 170 (17MXS1); 
320V 50Hz 700W 
Moist box   
Nitrile Examination gloves  Mikroflex 9953.01 
pH-meter  Metrohm 691 pH-meter 
Staining dishes Hellendahl 2460 
silver tray   
Water bath (37 °C, 55 °C)   
Table 2: Equipment for Comet Assay 
 
3.3.2. Reagents for Comet Assay 
Reagents Abbreviation Company Product no. 
Albumin from bovine serum BSA SIGMA Life science A2153-50G 
Dulbecco´s Phosphate 
Buffered Saline 
PBS SIGMA Life science D5837 
Ethylenediaminetetraacetic 
acid 
EDTA SIGMA Life science  
Ethidium bromide aqueous 
solution 
 SIGMA Life science E1510 
Hydrochloric Acid HCl Riedel-de Haen  
HEPES  SIGMA Life science  
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Hydrogen peroxide solution 
30 wt % solution in water 
H2O2 SIGMA Life science  
Potassium chloride KCl Riedel-de Haen 31248 
Potassium hydroxide KOH SIGMA -Aldrich 60370 
Sodium Chloride NaCl SIGMA-Aldrich 71380 
Sodium Hydroxide (Pellets) NaOH Riedel-de Haen 06203 
Trizma base  FLUKA Analytica 93350 
Triton X-100  SIGMA-Aldrich  
Trypan blue stain 0.4%  INVITROGEN T10282 
Ultra Pure Agarose NMA INVITROGEN 0000153001 
Ultra Pure LMP Agarose LMA INVITROGEN 0000144556 
Table 3: Reagents for Comet Assay 
 
3.3.3. Manufacturing process and storage of solutions for 
Comet Assay 
The reagents, used for the comet assay process, were manufactured according 
to the protocol “Protocol for the single cell gel electrophoresis/Comet Assay for 
rapid genotoxicity assessment” published by Dhawan et al. 
 
Alkaline electrophoresis buffer (pH > 13) 
24 g NaOH (0.3M) 
580 mg EDTA (0.001M) 
NaOH and EDTA were dissolved in 2 l double distilled H2O. PH should be 
higher than 13 and can be adjusted with NaOH. Stored at 4 °C in the cooling 
chamber. 
 
Enzyme reaction buffer for FPG and ENDOIII 
9.53 g HEPES (40 mM) 
7.46 g KCl (0.1 M) 
0.15 g EDTA (0.5 mM) 
0.2 g BSA (0.2 mg/ml) 
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HEPES, KCL, EDTA and BSA were dissolved in 1 l double distilled H2O and 
adjusted to pH 8.0 with KOH (1M). This buffer could also be made as 10x stock 
(adjusted with KOH (5M), be filled in aliquots and stored at -20 °C. Before 
usage the pH has to be controlled and adjust to 8 with KOH (5M). 
 
H2O2 Stock solution 
103 µl Hydrogen peroxide solution (30%) 
Double distilled H2O 
103 µl of the hydrogen peroxide solution was mixed with 10 ml double distilled 
H2O to receive a 0.1M stock. Before usage 80 µl of this 0.1M stock were mixed 
with 79.92 ml double distilled water and stored at 4 °C in the cooling chamber. 
 
Lysis Solution (pH = 10) 
146.1 g NaCl (2.5M) 
29.2 g EDTA (0.1M) 
1.211 g Tris (10mM) 
Double distilled H2O 
Triton X-100 
NaCl, EDTA and Tris were dissolved in 1 l double distilled H2O and the pH was 
adjusted to 10 with NaOH (10M). Solution was stored at room temperature. 
Triton X-100 (1 ml per 100 ml) was added just before use and then the solution 
was stored at 4 °C in the cooling chamber. 
 
NaOH (10N) 
400 g NaOH 
Double distilled H2O 
400 g NaOH were dissolved in 1 l double distilled H2O to receive a 10N NaOH 
solution. Stored at room temperature. 
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Neutralization buffer (pH = 7.5) 
48.44 g Tris base (0.4M) 
Double distilled H2O 
48.44 g Tris base (0.4M) were dissolved in 1 l double distilled H2O and the pH 
was adjusted to 7.5 with 37 % HCl. Buffer was stored at 4 °C in the cooling 
chamber. 
 
Normal Melting Agarose (NMA) 
1000 mg NMA 
Double distilled H2O 
1000 mg NMA were dissolved in 100 ml double distilled H2O, heated in 
microwave and stored at 4 °C in the cooling chamber. Before usage the 
agarose was heated up again in the microwave until it was liquefied. 
 
Low Melting Agarose (LMA) 
800 mg LMA 
80 ml PBS 
800 mg LMA were dissolved in 80 ml PBS, heated in microwave and stored at 
4 °C in the cooling chamber. Before usage the agarose was heated up again in 
the microwave until it was liquefied. 
 
Ethidium bromide solution 
20 µl ethidium bromide solution 
Double distilled H2O 
20 µl of ethidium bromide solution was mixed with 10 ml double distilled H2O to 
receive a concentration of 20 µg/ml. Stored at 4 °C in the fridge. 
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3.3.4. Protocol for Comet Assay
The Comet Assay was carried out according
single cell gel electrophoresis/Comet Assay for rapid genotoxicity assessment”
published by Dhawan et al. (w.y.
The general activity during the comet assay is illustrated in 
Figure 10: General activity of comet assay
 
For lysis, FPG, ENDOIII and buffer 3 gels were prepared and 2 gels for H
Each slide contained two gels and 2 
14 slides were prepared for 2 participants
Slides treated with lysis stayed 
were first treated with hydroperoxide 
electrophoresis. Slides treated with buffer, FPG or ENDOIII stayed 
solution (at least 7 minutes) 
Figure 10. 
 
 
 to the advices of “Protocol for the 
). 
Figure 10. 
    
 (left) and specific gels treatment (right) 
subjects (S1, S2) were mixed, in general
.  
in lysis solution all the time, whereas H2
and then kept in lysis solution
until treatment with enzymes started. See also
 
 
 
2O2. 
 
O2 slides 
 until 
in lysis 
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Slide preparation: 
• Prepared NMA was heated 3 times in microwave until it was completely 
liquefied and kept at 55 °C. 
• Slides were then dipped in the NMA-agarose and excess agarose was 
drained off. The backs of the slides were then wiped with a paper towel and 
air dried, before they were stored at room temperature.  
Embedding cells in agarose: (see Figure 11) 
• Prepared LMA was heated 3 times in microwave until it was completely 
liquefied and then kept warm at 37 °C in a water bath. 
• 30 µl of cell suspension (with a concentration of c= 1x106 cells per ml) was 
resuspended in a cup with 140 µl LMA.  
• 70 µl of this mixture were pipetted on a precoated slide, which was placed 
on cooled trays. On each slide there was place for two spots with a volume 
of 70 µl.  
• Each slide was covered with one cover slip (20x20 mm) and stayed in the 
cooling chamber for a minimum of 5 minutes before the cover slips got 
removed. 
Treatment with H2O2: 
• After the cover slips have been removed from the slides, they were placed in 
a staining jar containing a cooled H2O2 solution and incubated for 5 minutes 
in a cooling chamber (4 °C). 
• Then the slides were washed 3 times in PBS. 
Lysis: 
• After H2O2 incubation and removing the cover slips from all other slides, they 
were placed in the prepared lysis solution (lysis solution with 1 % triton X) for 
75 minutes in the cooling chamber.  
• Slides without H2O2 incubation were incubated separately from slides with 
H2O2 incubation. 
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Enzyme treatment: 
• Enzyme reaction buffer was prepared. 
• Slides for enzyme incubation were washed in staining jars with enzyme 
reaction buffer (4 °C) 3 times for 5 minutes respectively. 
• Enzyme dilutions (1:3000) were prepared.   
• Buffer was drained off the slides.  
• The agarose embedded cells (note: 2 gels/slide) were covered with 50 µl of 
either enzyme solution (FPG or ENDOIII) or enzyme reaction buffer (as 
negative control) and cover slips (22x22 mm). Slides were placed in a moist 
box and incubated in a drying chamber at 37 °C for 30 minutes.  
• All other slides (H2O2 and “no treatment”) stayed meanwhile in the lysis 
solution.  
Alkaline treatment and electrophoresis: (see Figure 12) 
• All cover slips were removed before they were placed in the electrophoresis. 
• The electrophoresis tank was placed in the cooling chamber at 4 °C. 
• Slides were placed on the platform in the electrophoresis tank with the gel 
upwards and the labelling areas towards the same direction. Incomplete 
rows were filled up with precoated but blank slides. (In every electrophoresis 
42 microscope slides had place that means 5 samples and one control 
sample.) 
• Slides were incubated in alkaline electrophoresis buffer for 20 minutes. 
(unwinding phase) 
• After the alkaline treatment, the electrophoresis was performed for 
30 minutes at around 300 mA, 25 V and 8 W. The current was adjusted by 
adding (if too low) or removing (if too high) alkaline electrophoresis buffer at 
a switched off power supply.  
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Neutralisation: 
• Slides were taken out from the electrophoresis and neutralized by rinsing 
5 minutes in cold neutralization buffer and another 5 minutes in double 
distilled water at 4 °C.  
• Finally the slides were dried at room temperature overnight in darkness and 
stored until staining.  
 Staining: 
• 30 µl of the ethidium bromide solution (20 µg/ml) was placed on the slide 
and covered with a coverslip (22x22 mm). 
• For examination two out of three slides were selected and always 50 cells 
per gel were counted. In case values of the two slides differed too much the 
third one was additionally determined.  
     
Figure 11: Slides on the tray before start of embedding cells in agarose. 
       
Figure 12: Electrophoresis (left) and lab work (right) 
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3.4. Statistically Analysis 
All statistical analysis was done with SPSS Statistics 17.0. Data was proved 
with 1-sample Kolmogorow-Smirnow-Test (KS-Test) for normal distribution.  
Boxplots were performed on all data in order to identify extreme values.  
Mean was compared using “Independent sample t-Test”, when comparing 
2 groups (Gilbert’s Syndrome and Control) and ANOVA-test (Tukey-HSD) was 
performed, when comparing more than 2 groups (UCB-levels in 3 groups).  
Correlations were tested with bivariate “Pearson Correlation” and linear 
regression was analysed stepwise. All results are expressed as mean values 
± standard deviation.  
If differences were significant (p<0.05) they are marked with *. If they were 
highly significant (p<0.01) they are marked with **. Results that were very high 
significant (p<0.001) are marked with ***. 
As already mentioned bilirubin levels (mean UCB levels) were divided in 
groups, mentioned as clear defined “Gilbert’s Syndrome” (UCB levels >1 mg/dl; 
[17.1 µmol/l]), “Control” (UCB levels <1 mg/dl; [17.1 µmol/l]) and “Not definable” 
(bilirubin levels around 1 mg/dl; [17.1 µmol/l]). In the group “Not definable” 
people with bilirubin levels around 17.1 µmol/l are included. Two measurements 
were performed and time values of UCB were once over and once under the 
threshold. Therefore, the group “Not definable” was not included in our statistics 
when GS and C group were compared. But bilirubin levels were also divided in 
three groups for statistically analysis, so they are mentioned as group 1 (low 
bilirubin: 0.24-0.65 mg/dl; [4.1-11.1 µmol/l]), group 2 (moderate bilirubin: 0.66-
1.21 mg/dl; [11.3-20.7 µmol/l]) and group 3 (high bilirubin: 1.22-4.3 mg/dl; [20.9-
73.5 µmol/l]) (with “not definable-group” included, n=16). 
Data was also interpreted stratified after gender and age. Age groups were 
defined as younger group (<30 year old test subjects) and older group (≥30 year 
old test subjects). 
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In the present diploma thesis results of lysis and H2O2 are presented. Results of 
the enzymes FPG and EndoIII treated samples are in the thesis of Nadja Antl 
“Effects of moderate hyperbilirubinaemia on DNA damage”.   
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4. Results and discussion 
Within the present study we wanted to examine, whether serum bilirubin has an 
antigenotoxic potential. Furthermore, it was an aim to figure out if people with 
higher bilirubin levels (GS) are better protected against oxidative stress and 
therefore have less DNA damage than control subjects. 
In the present study the very first Comet Assay data in Gilbert’s Syndrome is 
shown but there is no comparable literature available so far. 
 
Descriptive statistics: 
 Gilbert’s  
Syndrome 
Control Not definable 
Total  
sample size 
Men 35 23 12 70 
Women 10 16 4 30 
Total 45 39 16 100 
Table 4: Descriptive Statistics of the test subjects 
 
 Mean Age 
± SD 
Mean UCB levels 
± SD (mg/dl) 
p 
Total Subjects 31.6 ± 11.79 1.2 ± 0.89  
Gilbert’s 
Syndrome 
33.2 ± 13.04 1.9 ± 0.83*** 
<0.001 
Control 32.3 ± 11.60 0.5 ± 0.19*** 
Men 31.1 ± 11.71 1.4 ± 0.94** 
<0.01 
Women 32.8 ± 12.09 0.8 ± 0.62** 
Table 5: Comparison of mean age and mean UCB levels in the different groups 
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4.1. DNA damage  
4.1.1. Gilbert’s and Control Group 
In the following chapters 4.1.1, 4.2.1 and 4.3.1 unconjugated serum bilirubin 
data are separated in two groups defined as Gilbert’s Syndrome and control 
group. 
 
All test subjects N 
Mean ± SD 
(% DNA in tail) 
p 
Lysis Gilbert’s Syndrome 45 5.3±1.35 
n.s. 
Control  37 5.0±1.19 
H2O2 Gilbert’s Syndrome 45 19.6±4.91 n.s. 
Control 32 18.4±4.24 
Table 6: % DNA in tail in Gilbert’s (GS) and control (C) group (all test subjects) 
 
There were no significant differences between Gilbert’s and control group in 
single and double strand breaks.  
 
 
Figure 13: % DNA in tail in GS and C group (all test subjects) 
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4.1.2. UCB (unconjugated bilirubin) in 3 Groups 
Further we divided unconjugated serum bilirubin data in 3 groups: 
 group 1 (low bilirubin): 0.24-0.65 mg/dl 
 group 2 (moderate bilirubin): 0.66-1.21 mg/dl 
 groups 3 (high bilirubin): 1.22-4.3 mg/dl 
In the following chapters 4.1.2, 4.2.2 and 4.3.2 data was interpreted concerning 
these groups. 
 
All test subjects N 
Mean ± SD 
(% DNA in tail) 
Lysis Low bilirubin (1) 31 4.9±1.21 
Moderate bilirubin (2) 34 5.3±1.15 
High bilirubin (3) 33 5.1±1.33 
H2O2 Low bilirubin (1) 27 18.5±4.65 
Moderate bilirubin (2) 33 18.9±4.33 
High bilirubin (3) 33 19.0±5.01 
Table 7: DNA damage in all test subjects according to their bilirubin levels 
 
In all test subjects there were no significant differences observed in mean DNA 
damage concerning the 3 different bilirubin groups. 
 
 
Figure 14: DNA damage in all test subjects according to their bilirubin levels 
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4.1.3. Correlation of DNA Damage with Serum UCB 
<30 years Lysis H2O2  ≥30 years Lysis H2O2 
Lysis r 1 0.209  Lysis r 1 0.389* 
p  n.s. p  <0.05 
H2O2 r 0.209 1 H2O2 r 0.389
* 1 
p n.s.  p <0.05  
UCB r -0.020 -0.126 UCB r 0.124 0.369
* 
p n.s. n.s. p n.s. <0.05 
Table 8: Correlation of Comet Assay data with UCB regarding age (all test subjects) 
 
 
Figure 15: Correlation of H2O2 and UCB regarding age (all test subjects) 
 
Correlation between H2O2 and bilirubin in general was not significant. As you 
can see in Figure 15 the older group showed a positive correlation (r=0.369; 
p<0.05) between UCB and H2O2 induced DNA damage. 
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≥30 year old men Lysis H2O2 UCB 
Lysis r 1 0.334 0.215 
p  n.s. n.s. 
H2O2 r 0.334 1 0.583
** 
p n.s.  <0.01 
Table 9: Correlation of Comet Assay data with UCB (≥30 year old men) 
 
 
Figure 16: Correlation of H2O2 and UCB (≥30 year old men) 
 
The correlation was even stronger when only considering ≥30 year old male 
subjects for H2O2 and UCB levels (r=0.583; p<0.01). 
 
Since bilirubin has antioxidative potential our hypothesis was to find a negative 
correlation of bilirubin and DNA damage.  
In fact we found a strongly significant positive correlation in the ≥30 year old 
male subjects. Possible confounding factors like environmental factors, eating 
habits, or in general lifestyle of test subjects could have influenced the results. 
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With increasing age higher levels of oxidative stress occur in the body and at 
the same time antioxidants decrease [SOHAL and WEINDRUCH, 1996]. 
Further male gender is a risk factor for genetic damage [LAM et al., 2002]. Apart 
from the gender study participants had an average age of about 31.6 years. 
And in fact younger people are less affected by oxidative stress and might have 
a better immune system. Oxidative damage to DNA increases with the age, 
because cells lose more and more the ability to repair damaged DNA 
[HAMILTON et. al., 2001]. Fenech also observed in 1998 that micronuclei 
frequencies increase with the age and DNA damage is more often observed in 
older people than in younger test subjects [FENECH, 1998]. So this could also 
have influenced our study results.  
In our study you could also see that trends between young and old people were 
different. In the people older than 30 years a stronger but negative effect on 
DNA damage after stressing with H2O2 was shown. So bilirubin couldn’t protect 
DNA of oxidative damage due to H2O2. In young people UCB showed no 
negative trend on DNA. 
 
4.2. DNA damage: Stratified for gender 
4.2.1. Gilbert’s and Control Group 
Men and Women sex N 
Mean ± SD 
(% DNA in tail) 
Gilbert's 
Syndrome 
Lysis men 35 5.5±1.27 
women 10 4.5±1.36 
H2O2 men 35 19.8±5.06 
women 10 19.0±4.54 
Control Lysis men 22 5.1±1.23 
women 15 4.7±1.12 
H2O2 men 19 18.6±4.09 
women 13 18.1±4.60 
Table 10: % DNA in tail in GS and C group regarding sex 
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The mean value of DNA damage both in lysis and H2O2 showed no significance 
between men and women. In the control group the mean for men was 8.5 % 
higher for lysis and 2.8 % higher for H2O2 than for women. In the GS group the 
mean in men was 22.2 % higher for lysis and 4.2 % higher for H2O2 than in 
women. But in general the average mean of % DNA in tail in men was not 
significantly higher than in women.  
 
 
Figure 17: % DNA in tail in GS and C group regarding sex 
 
In fact there was no significant mean difference in lysis or H2O2 in all male test 
subjects as well as in all female test subjects. 
Lysis data for women with GS were 18.2 % lower than for men and in the 
control group women had 7.8 % lower DNA damage. 
In H2O2 results of lysis were similar as women with GS had 4 % lower mean 
values than men and in the control group 2.7 %.  
 
Concluding the results, men showed slightly higher DNA damage than women, 
without being significant. This result can be also confirmed by the study of Lam 
et al., who observed that male gender was associated as a risk factor for 
genetic damage [LAM et al., 2002].  
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Although in our study men were slightly less resistant towards oxidation by H2O2 
which was confirmed earlier by Bajpayee et al (2002), another study by 
Dusinska and Collins showed the opposite in 2008. This study showed that men 
tend to be more resistant towards H2O2 stress than women [BAJPAYEE et al., 
2002; DUSINSKA and COLLINS, 2008].   
 
4.2.2. UCB in 3 Groups 
Men N 
Mean  ± SD 
(% DNA in tail) 
Lysis Low bilirubin (1) 16 5.3±1.32 
Moderate bilirubin (2) 26 5.5±1.13 
High bilirubin (3) 27 5.3±1.26 
H2O2 Low bilirubin (1) 14 18.4±4.31 
Moderate bilirubin (2) 25 18.7±4.52 
High bilirubin (3) 27 19.2±5.13 
Table 11: DNA damage in men according to their bilirubin levels 
 
No significant difference in all groups for lysis and H2O2 was observed.   
Women N 
Mean ± SD 
(% DNA in tail) 
Lysis Low bilirubin (1) 15 4.5±0.95 
Moderate bilirubin (2) 8 4.9±1.19 
High bilirubin (3) 6 4.5±1.58 
H2O2 Low bilirubin (1) 13 18.6±5.16 
Moderate bilirubin (2) 8 19.5±3.87 
High bilirubin (3) 6 17.9±4.67 
Table 12: DNA damage in women according to their bilirubin levels 
 
In women there was no tendency for DNA damage in the different bilirubin 
groups in lysis and in H2O2. All results were not significant.  
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4.3. DNA damage: Stratified for age 
4.3.1. Gilbert’s and Control Group 
< 30 and ≥ 30 
age in 2 groups 
(years) 
N 
Mean ± SD 
(% DNA in tail) 
Gilbert's 
Syndrome 
Lysis <30 26 5.2±1.35 
≥30 19 5.4±1.37 
H2O2 <30 26 19.3±5.22 
≥30 19 20.0±4.55 
Control Lysis <30 23 4.8±1.14 
≥30 14 5.3±1.21 
H2O2 <30 20 18.9±3.94 
≥30 12 17.5±4.75 
Table 13: % DNA in tail in GS and C group regarding age (all test subjects) 
 
Divided in age groups there were no significant differences concerning mean 
DNA damage comparing test subjects <30 years with test subjects ≥30 years.  
 
 
Figure 18: % DNA in tail in GS and C group regarding age (all test subjects) 
 
In the control group the DNA damage (lysis) was 9.4 % (n.s.) lower in the 
younger subjects than in older. On the contrary by stressing with H2O2 the older 
groups had lower values (-7.4 %, n.s.).  
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Figure 19: % DNA in tail in age groups regarding GS and C group (all test subjects) 
 
There were no significant differences in lysis and in H2O2 challenging in mean 
DNA damage in all test subjects <30 years. 
Same results were found for test subjects ≥30 years.  
For lysis in the ≥30 year old subjects there was almost no difference (values for 
control group were just 1.9 % lower than in Gilbert’s group), as on the contrary 
in the <30 year old test subjects the mean DNA damage was 7.7 % lower in 
control group than in Gilbert’s Syndrome (n.s.).  
Furthermore, after H2O2 exposure the control group of the ≥30 year old test 
subjects showed a 12.5 % lower mean DNA damage than Gilbert’s Syndrome 
subjects. On the contrary in the <30 year old test subjects there was no 
noticeable difference (2.1 %). 
The younger GS group showed slightly higher DNA damage after lysis 
treatment, but on the contrary in the ≥30 year old GS group data for H2O2 
induced DNA damage was higher, but not significant.  
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4.3.2. UCB in 3 Groups 
< 30 years N 
Mean ± SD 
(% DNA in tail) 
Lysis Low bilirubin (1) 23 4.6±1.04 
Moderate bilirubin (2) 21 5.6±1.10 
High bilirubin (3) 17 4.8±1.29 
H2O2 Low bilirubin (1) 20 18.9±4.36 
Moderate bilirubin (2) 21 19.9±4.32 
High bilirubin (3) 17 18.0±5.12 
Table 14: DNA damage in <30 year old according to their bilirubin levels; Lysis 1 < 2 (p<0.05) 
 
 
Figure 20: DNA damage in <30 year old according to their bilirubin levels; Lysis 1 < 2 (p<0.05) 
 
After lysis a significant difference (p<0.05) in mean DNA damage was shown 
between the “low” and “moderate” bilirubin groups in the <30 year old. The 
difference was 17.9 %. Another difference between “moderate” and “high” 
bilirubin groups was “visible” but not significant. The DNA damage in the “high” 
bilirubin group was 14.3 % lower than in the “moderate” bilirubin group. As 
shown in Figure 20 the difference between “low” and “high” bilirubin groups was 
rather small.  
Results for H2O2 were similar to lysis but not significant. 
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>30 years N 
Mean ± SD 
(% DNA in tail) 
Lysis Low bilirubin (1) 8 5.6±1.45 
Moderate bilirubin (2) 13 4.9±1.14 
High bilirubin (3) 16 5.5±1.31 
H2O2 Low bilirubin (1) 7 17.5±5.65 
Moderate bilirubin (2) 12 17.1±3.89 
High bilirubin (3) 16 20.1±4.81 
Table 15: DNA damage in ≥30 year old according to their bilirubin levels 
 
 
Figure 21: DNA damage in ≥30 year old according to their bilirubin levels 
 
There were no significant differences in mean DNA damage in test 
subjects ≥30 years in lysis as well as in H2O2 however the mean DNA damage 
after stressing with H2O2 was 14.9 % lower in the “moderate” and “low” bilirubin 
group comparing to the “high” bilirubin group. 
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4.3.3. Correlation of DNA damage with age 
All test subjects Lysis H2O2 Age 
Lysis r 1 0.278** 0.077 
p  <0.01 n.s. 
H2O2 r 0.278
** 1 0.038 
p <0.01  n.s. 
Table 16: Correlation of Comet Assay data with age (all test subjects) 
 
There was no significant correlation of DNA damage with age neither in lysis 
nor in H2O2.  
Nevertheless there was a small difference in men and women after lysis. Only 
in women there was a trend that the DNA damage was increasing with the age 
(men: r=0.005; n.s.; women: r=0.326; n.s.). 
 
As known from other studies oxidative stress is increasing in the age [SOHAL 
and WEINDRUCH, 1996; KNIGHT, 2000]. Different studies showed an increase 
of oxidative damage with age due to following three causes: an increase in the 
generation of reactive oxygen species (ROS), a decrease in antioxidative 
defense and a decrease in the efficiency of repair or removal of damaged 
molecules. [SOHAL and WEINDRUCH, 1996]  
Therefore we expected to find an increase in mean DNA damage concerning 
the age of the test subjects in our study. Actually we were not able to prove this 
thesis, because our results were not significant so there was no increase in 
DNA damage with the age. The main reason might be the young age of the 
study group. There were only a few subjects (n=10) aged 50 years or older.  
In literature we could find some inconsistent information, whereas some studies 
found a difference concerning age in mean DNA damage others didn’t. So we 
could find confirmation for our results. Neither Pitarque and co-workers nor 
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Carere et al. (2002) could find any significant differences in the Comet assay or 
the tail moment concerning age. [PITARQUE et al., 1999; CARERE et al., 2002] 
 
4.4. Correlations 
We tested the correlation of lysis and H2O2 with unconjugated bilirubin (UCB), 
age, albumin, uric acid and BMI. Furthermore we made stratification for age 
groups and gender. 
 
4.4.1. Correlation of DNA damage with Serum Albumin 
<30 year old women Lysis H2O2 Serum Albumin 
Lysis r 1 0.161 -0.565
* 
p  n.s. <0.05 
H2O2 r 0.161 1 -0.569
* 
p n.s.  <0.05 
Table 17: Correlation of Comet Assay data with Serum albumin (<30 year old women) 
 
 
Figure 22: Correlation of H2O2 and Serum albumin (<30 year old women) 
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There was a highly significant negative correlation between H2O2 and albumin. 
Lower levels of albumins were associated with higher damage in DNA after 
stressing with H2O2. Especially in <30 year old women this correlation was very 
strong (r=-0.569; p<0.05). 
 
 
Figure 23: Correlation of H2O2 and Serum albumin regarding sex (all test subjects) 
 
DNA damage in women (r=-0.336; n.s.) showed a higher correlation with 
albumin than in men (r=-0.139; n.s.) but results were not significant. 
The results for lysis were significant in the younger women with a strong and 
negative correlation (r=-0.565; p<0.05). 
 
Women N Mean ± SD 
(g/l) 
Serum 
albumin 
low bilirubin (1) 16 44.6±2.77 
moderate bilirubin (2) 8 42.3±3.02
*
 
high bilirubin (3) 6 47.1±3.54
*
 
Total 30 44.5±3.32 
Table 18: Mean Serum albumin concentrations according to bilirubin levels in women 
(moderate UCB < high UCB; p<0.05) 
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<30 year old N Mean ± SD 
(g/l) 
Serum 
albumin 
low bilirubin (1) 23 46.4±3.11 
moderate bilirubin (2) 21 46.3±2.34
*
 
high bilirubin (3) 17 49.0±2.67
*
 
Total 61 47.1±2.96 
Table 19: Mean Serum albumin concentrations according to bilirubin levels in <30 year old 
subjects (moderate=low UCB < high UCB; p<0.05) 
 
We also observed a significant difference in serum albumin levels in women 
depending on the bilirubin plasma levels. Subjects <30 years of age showed 
higher albumin levels in the high bilirubin group compared to the moderate 
(p<0.01) and low bilirubin group (p<0.05). (see Table 19) 
Since albumin is the transporter of bilirubin in blood, elevated levels of bilirubin 
are linked to elevated levels of serum albumin.  
Albumin is the most important plasma protein and represents the first line in 
defense against reactive oxygen species (ROS) [CANDIANO et al., 2009].  
Albumin contains 585 amino acids and the regular plasma concentration in 
humans is between 35 and 50 g/l. Beside the transport of metals, fatty acids, 
cholesterol, bile pigments and drugs an important function is the regulation of 
the osmotic pressure and as important antioxidant in the plasma. In a pro-
inflammation state increased albumin concentrations could be found in order to 
exert its multiple antioxidant properties. [ROCHE et al., 2008]  
Previous mentioned bilirubin is bound to albumin in plasma and as studies 
already have tested albumin-bound bilirubin successfully competes with uric 
acid for peroxyl radicals [STOCKER at al., 1987].  
 
Free copper and iron can interact with hydrogen peroxide but bound to protein 
these metals are less susceptible for this reaction. Therefore high 
concentrations of circulating albumin can reduce the formation of hydroxyl 
radicals that are products of Fe-H2O2 interactions. [ROCHE et al., 2008] 
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Our study showed that after stressing PBMCs with H2O2 the DNA damage was 
higher at increasing albumin levels. This outcome was basically observed in 
women. 
In our study we could prove the hypothesis that albumin but especially albumin-
bound bilirubin, can act as antioxidant and can protect DNA from oxidation by 
H2O2.  
 
4.4.2. Correlation of DNA damage with Uric Acid 
All test subjects Lysis H2O2 Uric acid 
Lysis r 1 0.278** 0.426
*** 
p  <0.01 <0.001 
H2O2 r 0.278
** 1 0.010 
p <0.01  n.s. 
Table 20: Correlation of Comet Assay data with Uric acid (all test subjects) 
 
Men Lysis H2O2  Women Lysis H2O2 
Lysis r 1 0.290*  Lysis r 1 0.280 
p  <0.05 p  n.s. 
H2O2 r 0.290
* 1 H2O2 r 0.280 1 
p <0.05  p n.s.  
Uric Acid r 0.411
*** 
0.012 Uric Acid r 0.108 -0.017 
p <0.001 n.s. p n.s. n.s. 
Table 21: Correlation of Comet Assay data with Uric Acid regarding sex (all test subjects) 
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Figure 24: Correlation of Lysis and Uric acid regarding sex (all test subjects)      
 
<30 years Lysis H2O2  ≥30 years Lysis H2O2 
Lysis r 1 0.209  Lysis r 1 0.389* 
p  n.s. p  <0.05 
H2O2 r 0.209 1 H2O2 r 0.389
* 1 
p n.s.  p <0.05  
Uric acid r 0.533
*** -0.122 Uric acid r 0.273 0.238 
p <0.001 n.s. p n.s. n.s. 
Table 22: Correlation of Comet Assay data with Uric acid regarding age (all test subjects) 
 
 
Figure 25: Correlation of Lysis and Uric acid regarding age (all test subjects) 
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There was a strong positive correlation (r=0.426; p<0.001) between lysis and 
uric acid that was highly significant, showing that with higher levels of uric acid 
in blood the damage in DNA in lysis was increasing. This correlation was strong 
in men, but not seen in women (men: r=0.411, p<0.001; women: r=0.108, n.s.). 
Particularly the highest correlation was found in younger people 
(<30 years: r=0.533; p<0.001; ≥30 years: r=0.273; n.s.).  
We couldn’t find any significant correlations of uric acid with DNA damage after 
H2O2 challenge. 
 
In humans uric acid (C5H4N4O3) is the final breakdown product of purine 
nucleotides. Uric acid cannot be metabolised and is therefore excreted in urine. 
Elevated uric acid levels can be harmful and lead to gout. [HORN et al., 2005] 
In most other mammals, uric acid is oxidised by the enzyme uricase to allantoin. 
If this enzyme is not working at all higher primates lose the ability to synthesize 
ascorbic acid too. Both uric acid and ascorbic acid are strong electron donors 
and can therefore act as antioxidants. In humans uric acid is responsible for 
over half of the antioxidant capacity in blood plasma. [MAXWELL et al., 1997] 
However, uric acid is a double-edged sword. On one hand serum uric acid is a 
potent antioxidant that even might protect against cancer [KOLONEL et al., 
1994] and serve as biggest contributor to serum ferric reducing antioxidant 
power (FRAP) values [LEE et al., 2008]. On the other hand it is known that it is 
a strong predictor of cardiovascular disease mortality [NISKANEN et al., 2011]. 
It is also mentioned that uric acid may be an indicator for increased oxidative 
stress since xanthine oxidase, an enzyme in the degradation circle of purines to 
uric acid, has been shown to be an important source of superoxide free radicals 
[CULLETON et al., 1999]. (See also Figure 26). 
In cancer patients abnormal high levels of serum uric acid are often found as a 
result of increased nucleic acid turnover in the rapidly proliferating diseased 
tissue [KOLONEL at al., 1994]. 
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Figure 26: Purine metabolism from Adenosine to Uric acid [www.medscape.com; access date: 
29.4.2011] 
 
Uric acid N 
Mean ± SD 
(µmol/l) 
p 
Total 100 5.5±1.08  
Men 70 6.0±0.90*** 
<0.001 
Women 30 4.6±0.74*** 
Table 23: Mean values of Uric acid in the test subjects 
 
Our study showed a strong positive correlation between serum uric acid and 
mean DNA damage. Especially in men this outcome was very strong for lysis 
data. Further it was shown that men have higher uric acid levels which might 
also explain the higher DNA damage in men. (men: 6.0 µmol/l; women: 
4.6 µmol/l) 
 
 
62 
  
4.4.3. Correlation of DNA damage with BMI 
 
Figure 27: Correlation of Lysis and BMI regarding age (men) 
 
There was a significant positive but weak correlation between mean DNA 
damage (lysis) and BMI of male subjects (r=0.277; p<0.05). Especially in the 
≥30 year old men outcomes were stronger (r=0.416; p<0.05) than in the 
<30 year old men (r=0.195; n.s.). 
 
BMI N 
Mean ± SD 
(kg/m²) 
p 
<30 years 61 22.6±2.90** 
<0.01 
≥30 years 39 24.6±3.33** 
Table 24: Mean values of BMI in test subjects regarding age 
 
BMI N 
Mean ± SD 
(kg/m²) 
p 
Gilbert’s Syndrome 45 22.9±3.00 
n.s. 
Control  39 24.1±3.31 
Table 25: Mean values of BMI in test subjects regarding GS and C groups 
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Especially older people might have higher BMI values and have also other BMI 
classifications. As overweight can lead to oxidative stress BMI is an important 
factor. In our study test subjects ≥30 years generally had higher BMI levels than 
subjects <30 years and also mean of BMI was within normal BMI range. 
Differences were even significant (see Table 24). People with high BMI are 
more likely to suffer from oxidative stress related diseases like cardiovascular 
diseases or cancer [SINAIKO et al., 2005]. The higher BMI could be one reason 
for the negative impact of the older age group on DNA damage.  
Comparing the groups Gilbert’s syndrome and control there were the same 
results. Gilbert’s syndrome subjects had in general lower BMI levels than 
controls (see Table 25). Although this better outcome was not significant a trend 
could be observed (p=0.084).  
 
In conclusion we could find some interesting results regarding the correlation of 
lysis and H2O2 with uric acid, bilirubin, BMI and albumin.  
Uric acid levels were higher in men than in women which might explain the 
higher DNA damage in men that we observed.  
Generally serum albumin showed a higher correlation (negative) with DNA 
damage in women than in men. As already discussed albumin might have a 
protective role against oxidative stress and this could be a reason why women 
had less DNA damage than men in our study.  
 
4.5. Linear regression 
A linear regression analysis was performed with different variables, but no 
model was found for H2O2 treatment. However for lysis some of the results are 
shown. 
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4.5.1. Lysis 
 
Predictors Adjusted R² p 
Excluded  
variables 
All test subjects (98) 
Uric acid 
Uric acid and Albumin 
0.173*** 
0.226** 
<0.001 
<0.01 
 
Men (69) 
Uric acid 
Uric acid and Albumin 
0.156*** 
0.199* 
<0.001 
<0.05 
 
Women (29) Albumin 0.118* <0.05 Uric acid 
<30 years (61) 
Uric acid 
Uric acid and Albumin 
0.272*** 
0.322* 
<0.001 
<0.05 
 
<30 year old men (44) Uric acid 0.178** <0.01 Albumin 
<30 year old women (17) Albumin 0.273* <0.05 Uric acid 
Table 26: Linear regression model for DNA damage (Lysis data) 
  
Uric acid could explain 17.3 % of the lysis results and by including albumin 
22.6 % could be explained. 
For males the variable uric acid showed more influence whereas for females 
only albumin had a weak relevant impact.  
In the <30 year old test subjects uric acid could explain 27.2 % of the lysis 
results and by including albumin 32.2 %. 
In the ≥30 year old test subjects no linear regression could be found neither in 
male nor in female subjects.  
In the <30 year old male subjects 17.8 % of the lysis results could be explained 
by uric acid, whereas in the <30 year old women almost 30 % could be 
explained by albumin but for this subgroup total sample size (n=17) was already 
quite small.  
Considering the available data we can conclude that for men uric acid was the 
more influencing factor of DNA damage whereas for women it was albumin. 
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5. Conclusion 
With this study we wanted to examine, whether serum bilirubin has an 
antigenotoxic potential. Furthermore, it was an aim to figure out if people with 
higher bilirubin levels (GS) are better protected against oxidative stress and 
therefore have less DNA damage than control subjects.  
We couldn’t confirm our hypothesis because no significant differences in DNA 
damage between the Gilbert’s and the control group were found, as well as 
there were no significant differences in the 3 bilirubin percentiles. We were not 
able to find a significant inverse correlation between bilirubin and DNA damage 
in order to show that higher levels of bilirubin leads to a lower amount of strand 
breaks in DNA. 
But we found a positive correlation between DNA damage and serum uric acid, 
which means that in our study uric acid acted as oxidant especially in young 
men.  
There was also a negative correlation between DNA damage and serum 
albumin. We showed that higher albumin levels were associated with lower 
DNA damage. After stressing with H2O2 results were very clear for <30 year old 
women (p<0.05).  
We also were able to show that uric acid is a more influencing factor in men 
whereas for women it is albumin, what also proves our pervious statement. 
Another result was that BMI had an influence on DNA damage, especially in the 
older test subjects. In the groups older than 30 years the higher the BMI levels 
were the higher was DNA damage.  
Furthermore age had no influence on our results.  
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6. Summary 
Many epidemiological studies showed that elevated levels of serum bilirubin 
have a protective influence on cancer and cardiovascular diseases, since 
bilirubin acts as antioxidant. Particularly people with Gilbert’s Syndrome (GS), a 
harmless hyperbilirubinaemia, have elevated levels of unconjugated serum 
bilirubin and therefore might be better protected.   
The present case-control-study included 100 test subjects. All participants were 
randomly assigned to the GS or control group. The study was carried out at the 
Department of Nutritional Sciences at the University of Vienna. Participants 
were recruited by information-sheets, inclusion and exclusion criteria were 
checked by questionnaire.  
For measuring DNA damage and resistance to H2O2-induced DNA damage the 
comet assay was applied, which is a well established method for measuring 
single and double strand breaks.  
In fact we were not able to confirm our hypothesis that people with higher 
bilirubin levels (GS) are more protected against oxidative stress and therefore 
have less DNA damage than control subjects.  
But we found some interesting results on serum albumin and uric acid. Serum 
albumin worked as antioxidant and showed a more protecting effect on DNA 
than bilirubin especially in women. On the contrary high levels of uric acid were 
associated with higher DNA damage. Age had no influence on DNA damage 
but higher BMI levels correlated with a higher DNA damage, particularly in test 
subjects older than 30 years of age.    
As there is no comparable literature available so far, further studies on people 
with elevated bilirubin levels are needed to support the hypothesis of the 
beneficial effects of bilirubin on DNA.   
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7. Zusammenfassung 
Viele epidemiologische Studien zeigten, dass erhöhte Bilirubinspiegel einen 
schützenden Einfluss auf Krebs und kardiovaskuläre Erkrankungen haben, da 
Bilirubin als Antioxidans agiert. In Speziellen Personen mit Gilbert Syndrom 
(GS) - einer harmlosen Hyperbilirubinämie - haben erhöhte Werte von 
unkonjugiertem Serumbilirubin und sind daher möglicherweise besser 
geschützt.  
In dieser Fall-Kontroll-Studie nahmen 100 Testpersonen teil. Alle Teilnehmer 
wurden entweder der Gruppe Gilbert Syndrom oder Kontrolle zugeteilt. Die 
Studie wurde am Institut für Ernährungswissenschaften an der Universität Wien 
durchgeführt. Die durch Informationszettel angeworbenen Teilnehmer wurden 
mittels Fragebogen auf Ein- und Ausschlusskriterien überprüft.   
Für das Messen von DNA Schäden und der Resistenz gegenüber H2O2-
induzierten DNA Schäden wurde der „Comet Assay“ verwendet, welcher eine 
weit verbreitete Methode zum Messen von Einzel- und Doppelstrangbrüchen 
ist.  
Wir konnten unsere Hypothese, dass Menschen mit erhöhtem Bilirubinwert 
(GS) besser vor oxidativem Stress geschützt sind und daher weniger DNA 
Schäden aufweisen als die Kontrollprobanden, nicht beweisen.  
Aber wir konnten einige andere interessante Ergebnisse in Bezug auf 
Serumalbumin und Harnsäure finden. Serumalbumin wirkte als Antioxidans und 
zeigte eine höhere Schutzfunktion gegenüber der DNA als Bilirubin, vor allem 
bei Frauen. Im Gegensatz dazu beobachteten wir, dass hohe Werte von 
Harnsäure mit erhöhten DNA Schaden einhergingen. Das Alter hatte keinen 
Einfluss auf DNA Schäden allerdings korrelierte ein höherer BMI mit höheren 
DNA Schäden, besonders bei Studienteilnehmern älter als 30 Jahre.  
Es ist noch keine vergleichbare Literatur vorhanden, daher sind noch mehr 
Studien mit Personen mit erhöhtem Bilirubinwert notwendig, um die Hypothese, 
dass Bilirubin einen schützenden Effekt auf die DNA hat, zu prüfen.  
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9. Appendix 
a. Comparison of Gilbert’s and Control Group 
a.1. Differences concerning gender 
Men Classification in groups N Mean ± SD 
(% DNA in tail) 
p 
Lysis Gilbert’s Syndrome 35 5.5±1.27 
n.s. 
Control 22 5.1±1.23 
H2O2 Gilbert’s Syndrome 35 19.8±5.06 n.s. 
Control 19 18.6±4.09 
Table: Comparison of significant difference in mean in Gilbert’s and control group (men) 
 
Women Classification in groups N Mean ± SD 
(% DNA in tail) 
p 
Lysis Gilbert’s Syndrome 10 4.5±1.36 
n.s. 
Control 15 4.8±1.12 
H2O2 Gilbert’s Syndrome 10 19.0±4.54 n.s. 
Control 13 18.1±4.60 
Table: Comparison of significant difference in mean in Gilbert’s and control group (women) 
 
a.2. Differences concerning age 
<30 years Classification in groups N Mean ± SD 
(% DNA in tail) 
p 
Lysis Gilbert’s Syndrome 26 5.2±1.35 
n.s. 
Control 23 4.8±1.14 
H2O2 Gilbert’s Syndrome 26 19.3±5.22 n.s. 
Control 20 18.9±3.94 
Table: Comparison of significant difference in mean in Gilbert’s and control group (<30 years) 
 
≥30 years Classification in groups N Mean ± SD 
(% DNA in tail) 
p 
Lysis Gilbert’s Syndrome 19 5.4±1.37 
n.s. 
Control 14 5.3±1.21 
H2O2 Gilbert’s Syndrome 19 20.0±4.55 n.s. 
Control 12 17.5±4.75 
Table: Comparison of significant difference in mean in Gilbert’s and control group (≥30 years) 
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a.3. Differences concerning gender and age 
<30 year old men Classification in groups N Mean ± SD 
(% DNA in tail) 
p 
Lysis Gilbert’s Syndrome 22 5.4±1.31 
n.s. 
Control 14 5.0±1.13 
H2O2 Gilbert’s Syndrome 22 19.3±5.28 n.s. 
Control 12 19.1±3.66 
Table: Comparison of significant difference in Gilbert’s and control group (<30 year old men) 
 
≥30 year old men Classification in groups N Mean ± SD 
(% DNA in tail) 
p 
Lysis Gilbert’s Syndrome 13 5.7±1.23 
n.s. 
Control 8 5.4±1.42 
H2O2 Gilbert’s Syndrome 13 20.6±4.73 n.s. 
Control 7 17.6±4.91 
Table: Comparison of significant difference in Gilbert’s and control group (≥30 year old men) 
 
<30 year old women Classification in groups N Mean ± SD 
(% DNA in tail) 
p 
Lysis Gilbert’s Syndrome 4 4.1±1.04 
n.s. 
Control 9 4.4±1.14 
H2O2 Gilbert’s Syndrome 4 19.4±5.63 n.s. 
Control 8 18.6±4.57 
Table: Comparison of significant difference in Gilbert’s and control group (<30 year old women) 
 
≥30 year old women Classification in groups N Mean ± SD 
(% DNA in tail) 
p 
Lysis Gilbert’s Syndrome 6 4.8±1.55 
n.s. 
Control 6 5.2±0.98 
H2O2 Gilbert’s Syndrome 6 18.7±4.22 n.s. 
Control 5 17.3±5.07 
Table: Comparison of significant difference in Gilbert’s and control group (≥30 year old women) 
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b. Comparison of UCB bilirubin in 3 levels 
All test subjects Groups Groups p 
Lysis 1 2 
n.s. 1 3 
2 3 
H2O2 1 2 
n.s. 1 3 
2 3 
Table: Comparison of significant difference in mean in three groups of bilirubin (all test subjects) 
 
b.1. Differences concerning gender 
Men Groups Groups p 
Lysis 1 2 
n.s. 1 3 
2 3 
H2O2 1 2 
n.s. 1 3 
2 3 
Table: Comparison of significant difference in mean in three levels of bilirubin (men) 
 
Women Groups Groups p 
Lysis 1 2 
n.s. 1 3 
2 3 
H2O2 1 2 
n.s. 1 3 
2 3 
Table: Comparison of significant difference in mean in three levels of bilirubin (women) 
 
b.2. Differences concerning age 
< 30 years Group Group p 
Lysis 
1 2 <0.05 
1 3 
n.s. 
2 3 
H2O2 
1 2 
n.s. 1 3 
2 3 
Table: Comparison of significant difference in mean in three levels of bilirubin (<30 years) 
 
≥30 years Groups Groups p 
Lysis 1 2 
n.s. 1 3 
2 3 
H2O2 1 2 
n.s. 1 3 
2 3 
Table: Comparison of significant difference in mean in three levels of bilirubin (≥30 years) 
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c. Correlation 
c.1. Correlation between lysis and H2O2 with the age, albumin, bilirubin, 
uric acid, glutathione and creatinine 
All test subjects Lysis H2O2 Age Albumin UCB Uric acid Glutathione Creatinine 
Lysis r 1        
p 
 
       
H2O2 r 0.278
** 1       
p <0.01 
 
      
Age r 0.077 0.038 1      
p n.s. n.s. 
 
     
Albumin r -0.137 -0.182 -0.328** 1     
p n.s. n.s. <0.01 
 
    
UCB r 0.055 0.073 0.125 0.208* 1    
p n.s. n.s. n.s. <0.05 
 
   
Uric acid r 0.426*** 0.010 -0.075 0.235* 0.179 1   
p <0.001 n.s. n.s. <0.05 n.s. 
 
  
Glutathione r 0.225* 0.082 0.149 -0.245* -0.051 -0.151 1  
p <0.05 n.s. n.s. <0.05 n.s. n.s. 
 
 
Creatinine r 0.298** 0.095 -0.033 0.302** 0.129 0.537*** -0.229* 1 
p <0.01 n.s. n.s. <0.01 n.s. <0.001 <0.05 
 
Table: Correlation lysis and H2O2 with age, albumin, bilirubin, uric acid, glutathione and creatinine (all test subjects) 
 
Table: Correlation lysis and H2O2 with age, albumin, bilirubin, uric acid, glutathione and creatinine (men) 
Men Lysis H2O2 Age Albumin UCB Uric acid Glutathione Creatinine 
Lysis r 1        
p 
 
       
H2O2 r 0.290
* 1       
p <0.05 
 
      
Age r 0.005 0.036 1      
p n.s. n.s. 
 
     
Albumin r -0.244* -0.139 -0.517*** 1     
p <0.05 n.s. <0.001 
 
    
UCB r -0.013 0.098 0.153 0.036 1    
p n.s. n.s. n.s. n.s. 
 
   
Uric acid r 0.411*** 0.012 -0.144 -0.015 0.030 1   
p <0.001 n.s. n.s. n.s. n.s. 
 
  
Glutathione r 0.309** 0.138 0.065 -0.242* -0.019 -0.012 1  
p <0.01 n.s. n.s. <0.05 n.s. n.s. 
 
 
Creatinine r 0.106 0.113 -0.013 0.176 -0.070 0.221 -0.051 1 
p n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
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Women Lysis H2O2 Age Albumin UCB Uric acid Glutathione Creatinine 
Lysis r 1        
p 
 
       
H2O2 r 0.280 1       
p n.s. 
 
      
Age r 0.326 0.045 1      
p n.s. n.s. 
 
     
Albumin r -0.387* -0.336 0.009 1     
p <0.05 n.s. n.s. 
 
    
UCB r -0.050 -0.020 0.142 0.370* 1    
p n.s. n.s. n.s. <0.05 
 
   
Uric acid r 0.108 -0.017 0.235 0.005 -0.016 1   
p n.s. n.s. n.s. n.s. n.s. 
 
  
Glutathione r 0.315 -0.034 0.319 -0.058 0.093 -0.048 1  
p n.s. n.s. n.s. n.s. n.s. n.s. 
 
 
Creatinine r 0.308 0.165 0.130 -0.332 -0.154 0.042 -0.309 1 
p n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
 
Table: Correlation lysis and H2O2 with age, albumin, bilirubin, uric acid, glutathione and creatinine (women) 
 
<30 year olds Lysis H2O2 Age Albumin UCB Uric acid Glutathione Creatinine 
Lysis r 1        
p 
 
       
H2O2 r 0.209 1       
p n.s. 
 
      
Age r -0.014 0.060 1      
p n.s. n.s. 
 
     
Albumin r -0.072 -0.258 0.050 1     
p n.s. n.s. n.s. 
 
    
UCB r -0.020 -0.126 0.124 0.373** 1    
p n.s. n.s. n.s. <0.01 
 
   
Uric acid r 0.533*** -0.122 0.017 0.302* 0.212 1   
p <0.001 n.s. n.s. <0.05 n.s. 
 
  
Glutathione r 0.331** 0.190 -0.273* -0.167 0.083 -0.046 1  
p <0.01 n.s. <0.05 n.s. n.s. n.s. 
 
 
Creatinine r 0.362** 0.076 0.111 0.385** 0.186 0.632*** -0.234 1 
p <0.01 n.s. n.s. <0.01 n.s. <0.001 n.s. 
 
Table: Correlation lysis and H2O2 with age, albumin, bilirubin, uric acid, glutathione and creatinine (<30 year olds) 
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≥30 year olds Lysis H2O2 Age Albumin UCB Uric acid Glutathione Creatinine 
Lysis r 1        
p 
 
       
H2O2 r 0.389
* 1       
p <0.05 
 
      
Age r -0.044 0.178 1      
p n.s. n.s. 
 
     
Albumin r -0.158 -0.121 -0.252 1     
p n.s. n.s. n.s. 
 
    
UCB r 0.124 0.369* 0.083 0.084 1    
p n.s. <0.05 n.s. n.s. 
 
   
Uric acid r 0.273 0.238 -0.082 0.096 0.149 1   
p n.s. n.s. n.s. n.s. n.s. 
 
  
Glutathione r 0.014 -0.007 -0.337* -0.104 -0.329* -0.297 1  
p n.s. n.s. <0.05 n.s. <0.05 n.s. 
 
 
Creatinine r 0.211 0.121 -0.006 0.165 0.066 0.371* -0.233 1 
p n.s. n.s. n.s. n.s. n.s. <0.05 n.s. 
 
Table: Correlation lysis and H2O2 with age, albumin, bilirubin, uric acid, glutathione and creatinine (≥30 year olds) 
 
<30 year old men Lysis H2O2 Age Albumin UCB Uric acid Glutathione Creatinine 
Lysis r 1        
p 
 
       
H2O2 r 0.261 1       
p n.s. 
 
      
Age r -0.052 0.064 1      
p n.s. n.s. 
 
     
Albumin r -0.245 -0.097 0.010 1     
p n.s. n.s. n.s. 
 
    
UCB r -0.147 -0.152 0.104 0.253 1    
p n.s. n.s. n.s. n.s. 
 
   
Uric acid r 0.444** -0.130 -0.088 0.047 0.124 1   
p <0.01 n.s. n.s. n.s. n.s. 
 
  
Glutathione r 0.488** 0.261 -0.313* -0.170 0.116 0.112 1  
p <0.01 n.s. <0.05 n.s. n.s. n.s. 
 
 
Creatinine r 0.149 0.090 0.113 0.165 0.009 0.352* -0.172 1 
p n.s. n.s. n.s. n.s. n.s. <0.05 n.s. 
 
Table: Correlation lysis and H2O2 with age, albumin, bilirubin, uric acid, glutathione and creatinine (<30 year old men) 
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<30 year old women Lysis H2O2 Age Albumin UCB Uric acid Glutathione Creatinine 
Lysis r 1        
p 
 
       
H2O2 r 0.161 1       
p n.s. 
 
      
age r -0.014 0.064 1      
p n.s. n.s. 
 
     
Albumin r -0.565* -0.569* 0.021 1     
p <0.05 <0.05 n.s. 
 
    
UCB r -0.098 -0.022 0.131 0.421 1    
p n.s. n.s. n.s. n.s. 
 
   
Uric acid r 0.293 -0.183 0.190 -0.384 -0.492* 1   
p n.s. n.s. n.s. n.s. <0.05 
 
  
Glutathione r 0.087 -0.048 -0.081 -0.059 0.164 -0.285 1  
p n.s. n.s. n.s. n.s. n.s. n.s. 
 
 
Creatinine r 0.231 0.287 -0.047 -0.228 -0.112 0.160 -0.377 1 
p n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
 
Table: Correlation lysis and H2O2 with age, albumin, bilirubin, uric acid, glutathione and creatinine (<30 year old women) 
 
≥30 year old men Lysis H2O2 Age Albumin UCB Uric acid Glutathione Creatinine 
Lysis r 1        
p 
 
       
H2O2 r 0.334 1       
p n.s. 
 
      
Age r -0.110 0.100 1      
p n.s. n.s. 
 
     
Albumin r -0.233 -0.235 -0.385 1     
p n.s. n.s. n.s. 
 
    
UCB r 0.147 0.583* 0.141 -0.050 1    
p n.s. <0.05 n.s. n.s. 
 
   
Uric acid r 0.389 0.255 -0.119 -0.243 -0.086 1   
p n.s. n.s. n.s. n.s. n.s. 
 
  
Glutathione r -0.007 -0.036 -0.371 -0.051 -0.311 -0.139 1  
p n.s. n.s. n.s. n.s. n.s. n.s. 
 
 
Creatinine r 0.028 0.157 -0.044 0.233 -0.190 -0.039 0.180 1 
p n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
 
Table: Correlation lysis and H2O2 with age, albumin, bilirubin, uric acid, glutathione and creatinine (≥30 year old men) 
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≥30 year old women Lysis H2O2 Age Albumin UCB Uric acid Glutathione Creatinine 
Lysis r 1        
p 
 
       
H2O2 r 0.521 1       
p n.s. 
 
      
Age r 0.195 0.445 1      
p n.s. n.s. 
 
     
Albumin r -0.153 0.090 0.141 1     
p n.s. n.s. n.s. 
 
    
UCB r -0.136 0.046 -0.037 0.330 1    
p n.s. n.s. n.s. n.s. 
 
   
Uric acid r -0.131 0.204 0.135 0.453 0.313 1   
p n.s. n.s. n.s. n.s. n.s. 
 
  
Glutathione r 0.262 0.130 -0.433 0.014 -0.176 -0.149 1  
p n.s. n.s. n.s. n.s. n.s. n.s. 
 
 
Creatinine r 0.424 -0.047 0.514 -0.514 -0.192 -0.034 -0.380 1 
p n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
 
Table: Correlation lysis and H2O2 with age, albumin, bilirubin, uric acid, glutathione and creatinine (≥30 year old women) 
 
c.2. Correlation between lysis and H2O2 with vitamin C, homocysteine, 
iron, LDL, HDL, cholesterol and BMI 
 
All test subjects Lysis H2O2 Vitamin C Homocysteine Iron LDL HDL CHol BMI 
Lysis r 1         
p 
 
        
H2O2 r 0.278
** 1        
p <0.01 
 
       
Vitamin C r 0.057 0.000 1       
p n.s. n.s. 
 
      
Homocysteine r -0.010 0.062 0.043 1      
p n.s. n.s. n.s. 
 
     
Iron r -0.027 0.046 0.151 -0.051 1     
p n.s. n.s. n.s. n.s. 
 
    
LDL r -0.079 -0.150 0.002 0.053 0.095 1    
p n.s. n.s. n.s. n.s. n.s. 
 
   
HDL r -0.164 0.062 0.029 0.030 -0.053 -0.063 1   
p n.s. n.s. n.s. n.s. n.s. n.s. 
 
  
CHol r -0.118 -0.136 -0.026 0.059 0.060 0.925*** 0.247* 1  
p n.s. n.s. n.s. n.s. n.s. <0.001 <0.05 
 
 
BMI r 0.175 -0.128 -0.299** 0.085 -0.227* 0.363*** -0.240* 0.327** 1 
p n.s. n.s. <0.01 n.s. <0.05 <0.001 <0.05 <0.01 
 
Table: Correlation lysis and H2O2 with vitamin C, homocysteine, iron, HDL, LDL, Cholesterol and BMI (all test subjects) 
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Men Lysis H2O2 Vitamin C Homocysteine Iron LDL HDL CHol BMI 
Lysis r 1         
p 
 
        
H2O2 r 0.290
* 1        
p <0.05 
 
       
Vitamin C r 0.118 0.087 1       
p n.s. n.s. 
 
      
Homocysteine r -0.071 0.146 0.027 1      
p n.s. n.s. n.s. 
 
     
Iron r -0.131 0.018 0.080 -0.104 1     
p n.s. n.s. n.s. n.s. 
 
    
LDL r -0.074 -0.170 0.100 0.204 0.074 1    
p n.s. n.s. n.s. n.s. n.s. 
 
   
HDL r -0.137 -0.041 0.051 0.087 0.098 -0.030 1   
p n.s. n.s. n.s. n.s. n.s. n.s. 
 
  
CHol r -0.081 -0.204 0.078 0.239* 0.092 0.959*** 0.167 1  
p n.s. n.s. n.s. <0.05 n.s. <0.001 n.s. 
 
 
BMI r 0.277* -0.033 -0.148 0.205 -0.266* 0.348** -0.177 0.351** 1 
p <0.05 n.s. n.s. n.s. <0.05 <0.01 n.s. <0.01 
 
Table: Correlation lysis and H2O2 with vitamin C, homocysteine, iron, HDL, LDL, Cholesterol and BMI (men) 
 
Women Lysis H2O2 Vitamin C Homocysteine Iron LDL HDL CHol BMI 
Lysis r 1         
p 
 
        
H2O2 r 0.280 1        
p n.s. 
 
       
Vitamin C r 0.010 -0.184 1       
p n.s. n.s. 
 
      
Homocysteine r 0.098 -0.132 0.094 1      
p n.s. n.s. n.s. 
 
     
Iron r -0.061 0.113 0.384* 0.022 1     
p n.s. n.s. <0.05 n.s. 
 
    
LDL r -0.245 -0.101 -0.210 -0.485** 0.028 1    
p n.s. n.s. n.s. <0.01 n.s. 
 
   
HDL r 0.081 0.278 -0.095 0.025 0.033 0.015 1   
p n.s. n.s. n.s. n.s. n.s. n.s. 
 
  
CHol r -0.186 0.064 -0.285 -0.465* 0.023 0.872*** 0.428* 1  
p n.s. n.s. n.s. <0.05 n.s. <0.001 <0.05 
 
 
BMI r -0.080 -0.340 -0.538** -0.193 -0.263 0.401* -0.291 0.306 1 
p n.s. n.s. <0.01 n.s. n.s. <0.05 n.s. n.s. 
 
Table: Correlation lysis and H2O2 with vitamin C, homocysteine, iron, HDL, LDL, Cholesterol and BMI (women) 
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<30 year olds Lysis H2O2 Vitamin C Homocysteine Iron LDL HDL CHol BMI 
Lysis r 1         
p 
 
        
H2O2 r 0.209 1        
p n.s. 
 
       
Vitamin C r 0.185 0.041 1       
p n.s. n.s. 
 
      
Homocysteine r -0.047 0.143 0.099 1      
p n.s. n.s. n.s. 
 
     
Iron r -0.002 0.027 0.195 0.036 1     
p n.s. n.s. n.s. n.s. 
 
    
LDL r -0.119 -0.082 0.194 0.011 0.148 1    
p n.s. n.s. n.s. n.s. n.s. 
 
   
HDL r -0.229 0.061 -0.040 0.181 -0.157 -0.182 1   
p n.s. n.s. n.s. n.s. n.s. n.s. 
 
  
CHol r -0.204 -0.060 0.149 0.062 0.077 0.900*** 0.180 1  
p n.s. n.s. n.s. n.s. n.s. <0.001 n.s. 
 
 
BMI r 0.141 -0.166 -0.177 0.081 -0.181 0.217 -0.138 0.251 1 
p n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
 
Table: Correlation lysis and H2O2 with vitamin C, homocysteine, iron, HDL, LDL, Cholesterol and BMI (<30 year olds) 
 
≥30 year olds Lysis H2O2 Vitamin C Homocysteine Iron LDL HDL CHol BMI 
Lysis r 1         
p 
 
        
H2O2 r 0.389
* 1        
p <0.05 
 
       
Vitamin C r -0.096 -0.073 1       
p n.s. n.s. 
 
      
Homocysteine r -0.052 -0.029 0.013 1      
p n.s. n.s. n.s. 
 
     
Iron r -0.050 0.083 0.054 -0.159 1     
p n.s. n.s. n.s. n.s. 
 
    
LDL r -0.102 -0.223 -0.200 -0.051 0.104 1    
p n.s. n.s. n.s. n.s. n.s. 
 
   
HDL r -0.116 0.081 0.136 -0.246 0.195 0.010 1   
p n.s. n.s. n.s. n.s. n.s. n.s. 
 
  
CHol r -0.101 -0.209 -0.184 -0.110 0.147 0.945*** 0.274 1  
p n.s. n.s. n.s. n.s. n.s. <0.001 n.s. 
 
 
BMI r 0.151 -0.055 -0.438** -0.114 -0.267 0.429** -0.471** 0.289 1 
p n.s. n.s. <0.01 n.s. n.s. <0.01 <0.01 n.s. 
 
Table: Correlation lysis and H2O2 with vitamin C, homocysteine, iron, HDL, LDL, Cholesterol and BMI (≥30 year olds) 
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<30 year old men Lysis H2O2 Vitamin C Homocysteine Iron LDL HDL CHol BMI 
Lysis r 1         
p 
 
        
H2O2 r 0.261 1        
p n.s. 
 
       
Vitamin C r 0.354* 0.200 1       
p <0.05 n.s. 
 
      
Homocysteine r -0.093 0.253 0.226 1      
p n.s. n.s. n.s. 
 
     
Iron r -0.156 -0.013 0.138 0.008 1     
p n.s. n.s. n.s. n.s. 
 
    
LDL r -0.093 -0.067 0.218 0.133 0.229 1    
p n.s. n.s. n.s. n.s. n.s. 
 
   
HDL r -0.033 -0.011 -0.006 0.232 -0.039 -0.240 1   
p n.s. n.s. n.s. n.s. n.s. n.s. 
 
  
CHol r -0.094 -0.093 0.207 0.213 0.253 0.947*** 0.007 1  
p n.s. n.s. n.s. n.s. n.s. <0.001 n.s. 
 
 
BMI r 0.195 -0.095 -0.156 0.146 -0.196 0.252 -0.116 0.292 1 
p n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
 
Table: Correlation lysis and H2O2 with vitamin C, homocysteine, iron, HDL, LDL, Cholesterol, BMI (<30 year old men) 
 
<30 year old women Lysis H2O2 Vitamin C Homocysteine Iron LDL HDL CHol BMI 
Lysis r 1         
p 
 
        
H2O2 r 0.161 1        
p n.s. 
 
       
Vitamin C r 0.018 -0.336 1       
p n.s. n.s. 
 
      
Homocysteine r -0.045 -0.090 -0.170 1      
p n.s. n.s. n.s. 
 
     
Iron r -0.025 0.193 0.585* 0.026 1     
p n.s. n.s. <0.05 n.s. 
 
    
LDL r -0.336 -0.136 0.160 -0.435 -0.196 1    
p n.s. n.s. n.s. n.s. n.s. 
 
   
HDL r -0.319 0.207 -0.284 0.207 -0.100 -0.043 1   
p n.s. n.s. n.s. n.s. n.s. n.s. 
 
  
CHol r -0.405 0.034 -0.086 -0.350 -0.314 0.791*** 0.469 1  
p n.s. n.s. n.s. n.s. n.s. <0.001 n.s. 
 
 
BMI r 0.007 -0.359 -0.233 -0.101 -0.177 0.097 -0.214 0.133 1 
p n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
 
Table: Correlation lysis and H2O2 with vitamin C, homocysteine, iron, HDL, LDL, Cholesterol, BMI (<30 year old women) 
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≥30 year old men Lysis H2O2 Vitamin C Homocysteine Iron LDL HDL CHol BMI 
Lysis r 1         
p 
 
        
H2O2 r 0.334 1        
p n.s. 
 
       
Vitamin C r -0.230 -0.087 1       
p n.s. n.s. 
 
      
Homocysteine r -0.111 0.007 -0.235 1      
p n.s. n.s. n.s. 
 
     
Iron r -0.044 0.106 -0.076 -0.284 1     
p n.s. n.s. n.s. n.s. 
 
    
LDL r -0.113 -0.325 -0.039 0.111 -0.123 1    
p n.s. n.s. n.s. n.s. n.s. 
 
   
HDL r -0.338 -0.091 0.154 -0.166 0.610** 0.291 1   
p n.s. n.s. n.s. n.s. <0.01 n.s. 
 
  
CHol r -0.130 -0.353 -0.051 0.095 -0.041 0.972*** 0.396* 1  
p n.s. n.s. n.s. n.s. n.s. <0.001 <0.05 
 
 
BMI r 0.416* 0.097 -0.137 0.009 -0.345 0.263 -0.417* 0.202 1 
p <0.05 n.s. n.s. n.s. n.s. n.s. <0.05 n.s. 
 
Table: Correlation lysis and H2O2 with vitamin C, homocysteine, iron, HDL, LDL, Cholesterol, BMI (≥30 year old men) 
 
≥30 year old women Lysis H2O2 Vitamin C Homocysteine Iron LDL HDL CHol BMI 
Lysis r 1         
p 
 
        
H2O2 r 0.521 1        
p n.s. 
 
       
Vitamin C r 0.135 -0.049 1       
p n.s. n.s. 
 
      
Homocysteine r 0.058 -0.130 0.547 1      
p n.s. n.s. n.s. 
 
     
Iron r -0.156 0.026 0.188 -0.037 1     
p n.s. n.s. n.s. n.s. 
 
    
LDL r -0.245 -0.042 -0.530 -0.654* 0.244 1    
p n.s. n.s. n.s. <0.05 n.s. 
 
   
HDL r 0.352 0.472 0.154 -0.355 0.158 0.034 1   
p n.s. n.s. n.s. n.s. n.s. n.s. 
 
  
CHol r -0.089 0.135 -0.430 -0.728** 0.318 0.932*** 0.378 1  
p n.s. n.s. n.s. <0.01 n.s. <0.001 n.s. 
 
 
BMI r -0.241 -0.327 -0.764** -0.401 -0.351 0.601* -0.406 0.399 1 
p n.s. n.s. <0.01 n.s. n.s. <0.05 n.s. n.s. 
 
Table: Correlation lysis and H2O2 with vitamin C, homocysteine, iron, HDL, LDL, Cholesterol, BMI (≥30 year old women)
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